{
  "as_of_date": "October 14, 2025",
  "programs": [
    {
      "asset": "AKEEGA (niraparib/abiraterone)",
      "indication": "M1 Metastatic Castration-Sensitive Prostate Cancer",
      "phase": null,
      "trial_or_program": "AMPLITUDE",
      "partner": "TESARO, an oncology-focused business within GSK",
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT06392841",
          "title": "Hispanic/Latino and Non-Hispanic BlAck Patients Treated With niRaparib and Abiraterone Acetate Plus Prednisone for Metastatic hOrmone Sensitive Prostate Cancer With Deleterious Homologous recombinatioN Repair Alterations: a Phase II, Open Label studY",
          "overall_status": "WITHDRAWN",
          "phase": "Phase 2",
          "conditions": [
            "Metastatic Hormone-sensitive Prostate Cancer (mHSPC)",
            "Deleterious HRR Gene Mutation",
            "BRCA1 Gene Mutation",
            "BRCA2 Gene Mutation",
            "BRIP1 Gene Mutation",
            "CHEK2 Gene Mutation",
            "FANCA Gene Mutation",
            "PALB2 Gene Mutation",
            "RAD51B Gene Mutation",
            "RAD54L Gene Mutation"
          ],
          "lead_sponsor": "Qian Qin",
          "collaborators": [
            "UT Southwestern Comprehensive Cancer Center",
            "Janssen, LP"
          ],
          "interventions": [
            "Androgen Deprivation Therapy (ADT)",
            "Niraparib/Abiraterone Acetate DAT",
            "Abiraterone Acetate",
            "Prednisone",
            "Docetaxel"
          ],
          "last_update": "2025-10-20",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06392841"
        },
        {
          "nct_id": "NCT06212583",
          "title": "A Randomized Trial of High-risK metachroNous oligometastatIc Prostate Cancer With hiGh-risk Mutations Treated witH meTastasiS Directed Therapy and Niraparib/Abiraterone Acetate and Prednisone (KNIGHTS)",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Prostate Cancer",
            "Oligometastatic Disease"
          ],
          "lead_sponsor": "University of Maryland, Baltimore",
          "collaborators": [
            "Janssen Scientific Affairs, LLC"
          ],
          "interventions": [
            "niraparib/abiraterone acetate",
            "Stereotactic ablative radiation therapy (SABR)",
            "Androgen deprivation therapy (ADT)"
          ],
          "last_update": "2025-05-01",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06212583"
        },
        {
          "nct_id": "NCT05689021",
          "title": "Phase 2 Study of CJNJ-67652000 (Niraparib/Abiraterone Acetate Fixed-Dose Combination) and Prednisone for Metastatic Castration-Resistant Prostate Cancer Associated With SPOP Mutation With or Without Homologous Recombination Deficiency",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Castration-Resistant Prostate Carcinoma",
            "Metastatic Prostate Adenocarcinoma",
            "Stage IVB Prostate Cancer AJCC v8"
          ],
          "lead_sponsor": "Mayo Clinic",
          "collaborators": [],
          "interventions": [
            "Abiraterone Acetate/Niraparib",
            "Biospecimen Collection",
            "Bone Scan",
            "Computed Tomography",
            "Magnetic Resonance Imaging",
            "Prednisone"
          ],
          "last_update": "2026-01-07",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05689021"
        },
        {
          "nct_id": "NCT04577833",
          "title": "An Open-label, Randomized Study to Assess the Relative Bioavailability (BA) and Bioequivalence (BE) of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Prostatic Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Niraparib",
            "Abiraterone Acetate (AA)",
            "Prednisone"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04577833"
        },
        {
          "nct_id": "NCT04497844",
          "title": "A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Metastatic Castration-sensitive Prostate Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Niraparib",
            "Abiraterone acetate (AA)",
            "Prednisone",
            "Placebo for Niraparib"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04497844"
        },
        {
          "nct_id": "NCT03431350",
          "title": "A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Prostatic Neoplasms, Castration-Resistant"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Niraparib 200 mg",
            "Cetrelimab 240 mg",
            "Cetrelimab 480 mg",
            "Abiraterone acetate 1000 mg",
            "Prednisone 5 mg"
          ],
          "last_update": "2025-12-23",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03431350"
        },
        {
          "nct_id": "NCT03748641",
          "title": "A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Castration-Resistant Prostatic Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Niraparib",
            "Abiraterone Acetate",
            "Prednisone",
            "Placebo",
            "New Formulation of Niraparib and Abiraterone Acetate (AA)"
          ],
          "last_update": "2025-12-22",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03748641"
        },
        {
          "nct_id": "NCT03903835",
          "title": "ProBio: An Outcome-adaptive and Randomized Multi-arm Biomarker Driven Study in Patients With Metastatic Prostate Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Metastatic Castration-resistant Prostate Cancer (mCRPC)",
            "Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)"
          ],
          "lead_sponsor": "Karolinska Institutet",
          "collaborators": [
            "The Swedish Research Council",
            "Kom Op Tegen Kanker",
            "Janssen Pharmaceutica N.V., Belgium",
            "AstraZeneca",
            "Cancerfonden"
          ],
          "interventions": [
            "Enzalutamide Oral Capsule",
            "Abiraterone Oral Tablet",
            "Carboplatin",
            "Cabazitaxel 60 mg Solution for Injection",
            "Docetaxel Injectable Solution",
            "Radium Chloride Ra-223",
            "Niraparib plus Abiraterone acetate plus Prednisone",
            "Capivasertib plus Docetaxel",
            "Apalutamide",
            "Darolutamide"
          ],
          "last_update": "2025-04-09",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03903835"
        },
        {
          "nct_id": "NCT06329830",
          "title": "Safety and Anti-tumor Activity of Lutetium-177 (177Lu)-PSMA-617 Along With Niraparib and Abiraterone Acetate Plus Prednisone in Metastatic Castration Resistant Prostate Cancer - LUNAAR Study",
          "overall_status": "WITHDRAWN",
          "phase": "Phase 2",
          "conditions": [
            "Metastatic Prostate Cancer",
            "Castration-resistant Prostate Cancer",
            "Metastatic Castration-resistant Prostate Cancer"
          ],
          "lead_sponsor": "Baptist Health South Florida",
          "collaborators": [
            "Janssen Scientific Affairs, LLC"
          ],
          "interventions": [
            "177Lu-PSMA-617",
            "Niraparib abiraterone acetate",
            "Prednisone"
          ],
          "last_update": "2024-09-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06329830"
        },
        {
          "nct_id": "NCT05401214",
          "title": "Pre-Approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)",
          "overall_status": "APPROVED_FOR_MARKETING",
          "phase": null,
          "conditions": [
            "Metastatic Castration-resistant Prostate Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Niraparib plus Abiraterone Acetate (Nira/AA) combination",
            "Prednisone/Prednisolone"
          ],
          "last_update": "2025-06-13",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05401214"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "AKEEGA (niraparib/abiraterone)",
        "niraparib/abiraterone",
        "AKEEGA (niraparib",
        "abiraterone)"
      ]
    },
    {
      "asset": "DARZALEX (daratumumab)",
      "indication": "Smoldering Multiple Myeloma",
      "phase": null,
      "trial_or_program": "AQUILA",
      "partner": "Genmab A/S",
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT02874742",
          "title": "Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Lenalidomide",
            "Bortezomib",
            "Dexamethasone",
            "Daratumumab"
          ],
          "last_update": "2025-02-04",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02874742"
        },
        {
          "nct_id": "NCT05408026",
          "title": "A Phase II, Multicenter, Open-Label Study of the Combination of Pomalidomide, Bortezomib, Low-Dose Dexamethasone, and Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma",
          "overall_status": "WITHDRAWN",
          "phase": "Phase 2",
          "conditions": [
            "Relapsed or Refractory Multiple Myeloma"
          ],
          "lead_sponsor": "Alliance Foundation Trials, LLC.",
          "collaborators": [
            "Janssen, LP",
            "Celgene"
          ],
          "interventions": [
            "Daratumumab",
            "Pomalidomide"
          ],
          "last_update": "2023-01-27",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05408026"
        },
        {
          "nct_id": "NCT04497961",
          "title": "Daratumumab Versus Lenalidomide Maintenance Therapy for Multiple Myeloma: A Randomized Pilot Study Comparing Patient-Reported Health Related Quality of Life Measures With a Plant Based Nutrition Intervention Sub Study (NUTRIVENTION-4)",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Memorial Sloan Kettering Cancer Center",
          "collaborators": [
            "Janssen Scientific Affairs, LLC"
          ],
          "interventions": [
            "Lenalidomide",
            "Daratumumab",
            "Questionnaires",
            "Dietary Intervention"
          ],
          "last_update": "2025-09-11",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04497961"
        },
        {
          "nct_id": "NCT02076009",
          "title": "Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma",
          "overall_status": "COMPLETED",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Daratumumab",
            "Lenalidomide",
            "Dexamethasone"
          ],
          "last_update": "2025-05-01",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02076009"
        },
        {
          "nct_id": "NCT05300451",
          "title": "A Phase II Prospective Study Evaluating the Role of Daratumumab in HLA Desensitization Prior to Transplantation",
          "overall_status": "ENROLLING_BY_INVITATION",
          "phase": "Phase 2",
          "conditions": [
            "Cardiac Transplant"
          ],
          "lead_sponsor": "Barry A. Boilson",
          "collaborators": [
            "Janssen Biotech, Inc."
          ],
          "interventions": [
            "Daratumumab and hyaluronidase-fihj"
          ],
          "last_update": "2025-10-30",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05300451"
        },
        {
          "nct_id": "NCT06918002",
          "title": "A Phase 3, Open-label, Controlled, Randomized Study of Newly Diagnosed Multiple Myeloma Treatment, Designed to Evaluate the Efficacy and Safety of the Elranatamab-lenalidomide Combination as a Replacement for Chemotherapy Followed by Autologous Stem Cell Transplant in the Consolidation Phase, and to Compare Elranatamab With Standard of Care in the Maintenance Phase",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma, Newly Diagnosed"
          ],
          "lead_sponsor": "Intergroupe Francophone du Myelome",
          "collaborators": [
            "Pfizer"
          ],
          "interventions": [
            "Elranatamab",
            "Lenalidomide (Revlimid®)",
            "Daratumumab SC (Darzalex)",
            "Autologous Stem Cell Transplantation",
            "Bortezomib (Velcade®)",
            "Dexamethasone"
          ],
          "last_update": "2025-07-16",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06918002"
        },
        {
          "nct_id": "NCT07297563",
          "title": "A Randomized, Open-label Study To Compare The Efficacy And Safety Of Anti-CD38 Monoclonal Antibody Versus Rituximab in ITP Patients Who Failed or Relapsed After Glucocorticoid Therapy",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Immune Thrombocytopenia",
            "Treatment"
          ],
          "lead_sponsor": "Institute of Hematology & Blood Diseases Hospital, China",
          "collaborators": [],
          "interventions": [
            "Rituximab",
            "Daratumumab"
          ],
          "last_update": "2025-12-22",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07297563"
        },
        {
          "nct_id": "NCT07285239",
          "title": "Randomized Phase 3 Trial of Belantamab Mafodotin or Daratumumab in Combination With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "PrECOG, LLC.",
          "collaborators": [
            "GlaxoSmithKline"
          ],
          "interventions": [
            "Arm A: Belantamab Mafodotin",
            "Arm B: Daratumumab Hyaluronidase",
            "Bortezomib",
            "Lenalidomide",
            "Dexamethasone"
          ],
          "last_update": "2025-12-16",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07285239"
        },
        {
          "nct_id": "NCT06192979",
          "title": "Optimize First-line Treatment for Systemic Light Chain Amyloidosis With t (11; 14)",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Amyloidosis; Systemic",
            "AL Amyloidosis"
          ],
          "lead_sponsor": "Jin Lu, MD",
          "collaborators": [],
          "interventions": [
            "Daratumumab",
            "Bortezomib",
            "Dexamethasone",
            "Venetoclax"
          ],
          "last_update": "2024-02-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06192979"
        },
        {
          "nct_id": "NCT04661137",
          "title": "A Phase 2B Study of Selinexor (KPT-330), in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma Relapsing on Current Therapy",
          "overall_status": "SUSPENDED",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Hackensack Meridian Health",
          "collaborators": [
            "Karyopharm Therapeutics Inc"
          ],
          "interventions": [
            "Selinexor 60 MG",
            "Selinexor 80 MG",
            "Selinexor 100 MG",
            "Carfilzomib",
            "Pomalidomide",
            "Daratumumab",
            "Dexamethasone"
          ],
          "last_update": "2025-02-25",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04661137"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "DARZALEX (daratumumab)",
        "daratumumab",
        "DARZALEX"
      ]
    },
    {
      "asset": "DARZALEX (daratumumab)",
      "indication": "Frontline multiple myeloma transplant ineligible",
      "phase": null,
      "trial_or_program": "CEPHEUS",
      "partner": "Genmab A/S",
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT02874742",
          "title": "Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Lenalidomide",
            "Bortezomib",
            "Dexamethasone",
            "Daratumumab"
          ],
          "last_update": "2025-02-04",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02874742"
        },
        {
          "nct_id": "NCT05408026",
          "title": "A Phase II, Multicenter, Open-Label Study of the Combination of Pomalidomide, Bortezomib, Low-Dose Dexamethasone, and Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma",
          "overall_status": "WITHDRAWN",
          "phase": "Phase 2",
          "conditions": [
            "Relapsed or Refractory Multiple Myeloma"
          ],
          "lead_sponsor": "Alliance Foundation Trials, LLC.",
          "collaborators": [
            "Janssen, LP",
            "Celgene"
          ],
          "interventions": [
            "Daratumumab",
            "Pomalidomide"
          ],
          "last_update": "2023-01-27",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05408026"
        },
        {
          "nct_id": "NCT04497961",
          "title": "Daratumumab Versus Lenalidomide Maintenance Therapy for Multiple Myeloma: A Randomized Pilot Study Comparing Patient-Reported Health Related Quality of Life Measures With a Plant Based Nutrition Intervention Sub Study (NUTRIVENTION-4)",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Memorial Sloan Kettering Cancer Center",
          "collaborators": [
            "Janssen Scientific Affairs, LLC"
          ],
          "interventions": [
            "Lenalidomide",
            "Daratumumab",
            "Questionnaires",
            "Dietary Intervention"
          ],
          "last_update": "2025-09-11",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04497961"
        },
        {
          "nct_id": "NCT02076009",
          "title": "Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma",
          "overall_status": "COMPLETED",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Daratumumab",
            "Lenalidomide",
            "Dexamethasone"
          ],
          "last_update": "2025-05-01",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02076009"
        },
        {
          "nct_id": "NCT05300451",
          "title": "A Phase II Prospective Study Evaluating the Role of Daratumumab in HLA Desensitization Prior to Transplantation",
          "overall_status": "ENROLLING_BY_INVITATION",
          "phase": "Phase 2",
          "conditions": [
            "Cardiac Transplant"
          ],
          "lead_sponsor": "Barry A. Boilson",
          "collaborators": [
            "Janssen Biotech, Inc."
          ],
          "interventions": [
            "Daratumumab and hyaluronidase-fihj"
          ],
          "last_update": "2025-10-30",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05300451"
        },
        {
          "nct_id": "NCT06918002",
          "title": "A Phase 3, Open-label, Controlled, Randomized Study of Newly Diagnosed Multiple Myeloma Treatment, Designed to Evaluate the Efficacy and Safety of the Elranatamab-lenalidomide Combination as a Replacement for Chemotherapy Followed by Autologous Stem Cell Transplant in the Consolidation Phase, and to Compare Elranatamab With Standard of Care in the Maintenance Phase",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma, Newly Diagnosed"
          ],
          "lead_sponsor": "Intergroupe Francophone du Myelome",
          "collaborators": [
            "Pfizer"
          ],
          "interventions": [
            "Elranatamab",
            "Lenalidomide (Revlimid®)",
            "Daratumumab SC (Darzalex)",
            "Autologous Stem Cell Transplantation",
            "Bortezomib (Velcade®)",
            "Dexamethasone"
          ],
          "last_update": "2025-07-16",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06918002"
        },
        {
          "nct_id": "NCT07297563",
          "title": "A Randomized, Open-label Study To Compare The Efficacy And Safety Of Anti-CD38 Monoclonal Antibody Versus Rituximab in ITP Patients Who Failed or Relapsed After Glucocorticoid Therapy",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Immune Thrombocytopenia",
            "Treatment"
          ],
          "lead_sponsor": "Institute of Hematology & Blood Diseases Hospital, China",
          "collaborators": [],
          "interventions": [
            "Rituximab",
            "Daratumumab"
          ],
          "last_update": "2025-12-22",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07297563"
        },
        {
          "nct_id": "NCT07285239",
          "title": "Randomized Phase 3 Trial of Belantamab Mafodotin or Daratumumab in Combination With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "PrECOG, LLC.",
          "collaborators": [
            "GlaxoSmithKline"
          ],
          "interventions": [
            "Arm A: Belantamab Mafodotin",
            "Arm B: Daratumumab Hyaluronidase",
            "Bortezomib",
            "Lenalidomide",
            "Dexamethasone"
          ],
          "last_update": "2025-12-16",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07285239"
        },
        {
          "nct_id": "NCT06192979",
          "title": "Optimize First-line Treatment for Systemic Light Chain Amyloidosis With t (11; 14)",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Amyloidosis; Systemic",
            "AL Amyloidosis"
          ],
          "lead_sponsor": "Jin Lu, MD",
          "collaborators": [],
          "interventions": [
            "Daratumumab",
            "Bortezomib",
            "Dexamethasone",
            "Venetoclax"
          ],
          "last_update": "2024-02-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06192979"
        },
        {
          "nct_id": "NCT04661137",
          "title": "A Phase 2B Study of Selinexor (KPT-330), in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma Relapsing on Current Therapy",
          "overall_status": "SUSPENDED",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Hackensack Meridian Health",
          "collaborators": [
            "Karyopharm Therapeutics Inc"
          ],
          "interventions": [
            "Selinexor 60 MG",
            "Selinexor 80 MG",
            "Selinexor 100 MG",
            "Carfilzomib",
            "Pomalidomide",
            "Daratumumab",
            "Dexamethasone"
          ],
          "last_update": "2025-02-25",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04661137"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "DARZALEX (daratumumab)",
        "daratumumab",
        "DARZALEX"
      ]
    },
    {
      "asset": "IMBRUVICA (ibrutinib)",
      "indication": "Frontline Chronic Lymphocytic Leukemia (I + V fixed duration)",
      "phase": null,
      "trial_or_program": "GLOW",
      "partner": "Pharmacyclics, LLC, an AbbVie company",
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT04016636",
          "title": "\"Impact of Ibrutinib on the Quality of Life (QOL) in Patients With Chronic Lymphocytic Leukemia (CLL): Argentinian Experience\"",
          "overall_status": "COMPLETED",
          "phase": null,
          "conditions": [
            "CLL"
          ],
          "lead_sponsor": "Mela Osorio Maria Jose",
          "collaborators": [
            "Janssen-Cilag Ltd."
          ],
          "interventions": [
            "Standard of Care"
          ],
          "last_update": "2023-02-16",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04016636"
        },
        {
          "nct_id": "NCT02556892",
          "title": "Phase 1 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Subjects With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
          "overall_status": "COMPLETED",
          "phase": "Phase 1",
          "conditions": [
            "Lymphocytic Leukemia"
          ],
          "lead_sponsor": "Janssen Pharmaceutical K.K.",
          "collaborators": [],
          "interventions": [
            "Ibrutinib"
          ],
          "last_update": "2019-08-14",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02556892"
        },
        {
          "nct_id": "NCT02959944",
          "title": "A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host Disease (cGVHD)",
          "overall_status": "COMPLETED",
          "phase": "Phase 3",
          "conditions": [
            "Chronic Graft Versus Host Disease"
          ],
          "lead_sponsor": "Pharmacyclics LLC.",
          "collaborators": [
            "Janssen Research & Development, LLC"
          ],
          "interventions": [
            "ibrutinib",
            "Placebo",
            "Prednisone"
          ],
          "last_update": "2023-03-30",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02959944"
        },
        {
          "nct_id": "NCT02758665",
          "title": "A Prospective, Open-label, Multicentre Phase-II Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Physically Fit or Unfit Patients With Previously Untreated Chronic Lymphocytic Leukemia (Cll) With tp53 Deletion (17p-) and/or Mutation",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Leukemia, Lymphocytic, Chronic"
          ],
          "lead_sponsor": "University of Ulm",
          "collaborators": [
            "German CLL Study Group",
            "Roche Pharma AG",
            "Janssen-Cilag Ltd.",
            "AbbVie"
          ],
          "interventions": [
            "ibrutinib",
            "obinutuzumab",
            "venetoclax"
          ],
          "last_update": "2023-01-17",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02758665"
        },
        {
          "nct_id": "NCT02532257",
          "title": "An Open Label, Phase 2 Study of Ibrutinib in Combination With Rituximab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma and Marginal Zone Lymphoma",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Ann Arbor Stage II Follicular Lymphoma",
            "Ann Arbor Stage II Marginal Zone Lymphoma",
            "Ann Arbor Stage III Follicular Lymphoma",
            "Ann Arbor Stage III Marginal Zone Lymphoma",
            "Ann Arbor Stage IV Follicular Lymphoma",
            "Ann Arbor Stage IV Marginal Zone Lymphoma",
            "CD20 Positive",
            "Grade 1 Follicular Lymphoma",
            "Grade 2 Follicular Lymphoma",
            "Grade 3a Follicular Lymphoma"
          ],
          "lead_sponsor": "M.D. Anderson Cancer Center",
          "collaborators": [
            "National Cancer Institute (NCI)",
            "Janssen, LP"
          ],
          "interventions": [
            "Ibrutinib",
            "Laboratory Biomarker Analysis",
            "Lenalidomide",
            "Rituximab"
          ],
          "last_update": "2024-09-24",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02532257"
        },
        {
          "nct_id": "NCT02717611",
          "title": "A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Chronic Lymphocytic Leukemia"
          ],
          "lead_sponsor": "Acerta Pharma BV",
          "collaborators": [],
          "interventions": [
            "ACP-196 (acalabrutinib)"
          ],
          "last_update": "2026-01-08",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02717611"
        },
        {
          "nct_id": "NCT01886872",
          "title": "A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥ 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Stage I Chronic Lymphocytic Leukemia",
            "Stage II Chronic Lymphocytic Leukemia",
            "Stage III Chronic Lymphocytic Leukemia",
            "Stage IV Chronic Lymphocytic Leukemia"
          ],
          "lead_sponsor": "National Cancer Institute (NCI)",
          "collaborators": [],
          "interventions": [
            "Bendamustine Hydrochloride",
            "Biospecimen Collection",
            "Bone Marrow Aspiration",
            "Bone Marrow Biopsy",
            "Computed Tomography",
            "Ibrutinib",
            "Laboratory Biomarker Analysis",
            "Quality-of-Life Assessment",
            "Rituximab"
          ],
          "last_update": "2025-11-28",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT01886872"
        },
        {
          "nct_id": "NCT04908228",
          "title": "Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Chronic Lymphocytic Leukemia"
          ],
          "lead_sponsor": "Paolo Ghia",
          "collaborators": [],
          "interventions": [
            "Ibrutinib and obinutuzumab"
          ],
          "last_update": "2023-10-03",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04908228"
        },
        {
          "nct_id": "NCT02268851",
          "title": "A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination With Ibrutinib in Patients With Select B-Cell Malignancies",
          "overall_status": "COMPLETED",
          "phase": "Phase 1",
          "conditions": [
            "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
            "Mantle Cell Lymphoma"
          ],
          "lead_sponsor": "Dana-Farber Cancer Institute",
          "collaborators": [
            "TG Therapeutics, Inc.",
            "The Leukemia and Lymphoma Society",
            "Blood Cancer Research Partnership"
          ],
          "interventions": [
            "TGR-1202",
            "Ibrutinib"
          ],
          "last_update": "2024-11-15",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02268851"
        },
        {
          "nct_id": "NCT02455297",
          "title": "A Single-arm, Open-label Phase IIa Study to Evaluate the Efficacy and Safety of Copanlisib Monotherapy in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL), Who Failed Ibrutinib Treatment or Were Unable to Tolerate Ibrutinib",
          "overall_status": "TERMINATED",
          "phase": "Phase 2",
          "conditions": [
            "Lymphoma, Mantle-Cell"
          ],
          "lead_sponsor": "Bayer",
          "collaborators": [],
          "interventions": [
            "Copanlisib (BAY80-6946)"
          ],
          "last_update": "2017-10-02",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02455297"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "IMBRUVICA (ibrutinib)",
        "ibrutinib",
        "IMBRUVICA"
      ]
    },
    {
      "asset": "IMBRUVICA (ibrutinib)",
      "indication": "Frontline Mantle Cell Lymphoma",
      "phase": null,
      "trial_or_program": "Triangle",
      "partner": "Pharmacyclics, LLC, an AbbVie company",
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT04016636",
          "title": "\"Impact of Ibrutinib on the Quality of Life (QOL) in Patients With Chronic Lymphocytic Leukemia (CLL): Argentinian Experience\"",
          "overall_status": "COMPLETED",
          "phase": null,
          "conditions": [
            "CLL"
          ],
          "lead_sponsor": "Mela Osorio Maria Jose",
          "collaborators": [
            "Janssen-Cilag Ltd."
          ],
          "interventions": [
            "Standard of Care"
          ],
          "last_update": "2023-02-16",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04016636"
        },
        {
          "nct_id": "NCT02556892",
          "title": "Phase 1 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Subjects With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
          "overall_status": "COMPLETED",
          "phase": "Phase 1",
          "conditions": [
            "Lymphocytic Leukemia"
          ],
          "lead_sponsor": "Janssen Pharmaceutical K.K.",
          "collaborators": [],
          "interventions": [
            "Ibrutinib"
          ],
          "last_update": "2019-08-14",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02556892"
        },
        {
          "nct_id": "NCT02959944",
          "title": "A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host Disease (cGVHD)",
          "overall_status": "COMPLETED",
          "phase": "Phase 3",
          "conditions": [
            "Chronic Graft Versus Host Disease"
          ],
          "lead_sponsor": "Pharmacyclics LLC.",
          "collaborators": [
            "Janssen Research & Development, LLC"
          ],
          "interventions": [
            "ibrutinib",
            "Placebo",
            "Prednisone"
          ],
          "last_update": "2023-03-30",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02959944"
        },
        {
          "nct_id": "NCT02758665",
          "title": "A Prospective, Open-label, Multicentre Phase-II Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Physically Fit or Unfit Patients With Previously Untreated Chronic Lymphocytic Leukemia (Cll) With tp53 Deletion (17p-) and/or Mutation",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Leukemia, Lymphocytic, Chronic"
          ],
          "lead_sponsor": "University of Ulm",
          "collaborators": [
            "German CLL Study Group",
            "Roche Pharma AG",
            "Janssen-Cilag Ltd.",
            "AbbVie"
          ],
          "interventions": [
            "ibrutinib",
            "obinutuzumab",
            "venetoclax"
          ],
          "last_update": "2023-01-17",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02758665"
        },
        {
          "nct_id": "NCT02532257",
          "title": "An Open Label, Phase 2 Study of Ibrutinib in Combination With Rituximab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma and Marginal Zone Lymphoma",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Ann Arbor Stage II Follicular Lymphoma",
            "Ann Arbor Stage II Marginal Zone Lymphoma",
            "Ann Arbor Stage III Follicular Lymphoma",
            "Ann Arbor Stage III Marginal Zone Lymphoma",
            "Ann Arbor Stage IV Follicular Lymphoma",
            "Ann Arbor Stage IV Marginal Zone Lymphoma",
            "CD20 Positive",
            "Grade 1 Follicular Lymphoma",
            "Grade 2 Follicular Lymphoma",
            "Grade 3a Follicular Lymphoma"
          ],
          "lead_sponsor": "M.D. Anderson Cancer Center",
          "collaborators": [
            "National Cancer Institute (NCI)",
            "Janssen, LP"
          ],
          "interventions": [
            "Ibrutinib",
            "Laboratory Biomarker Analysis",
            "Lenalidomide",
            "Rituximab"
          ],
          "last_update": "2024-09-24",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02532257"
        },
        {
          "nct_id": "NCT02717611",
          "title": "A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Chronic Lymphocytic Leukemia"
          ],
          "lead_sponsor": "Acerta Pharma BV",
          "collaborators": [],
          "interventions": [
            "ACP-196 (acalabrutinib)"
          ],
          "last_update": "2026-01-08",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02717611"
        },
        {
          "nct_id": "NCT01886872",
          "title": "A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥ 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Stage I Chronic Lymphocytic Leukemia",
            "Stage II Chronic Lymphocytic Leukemia",
            "Stage III Chronic Lymphocytic Leukemia",
            "Stage IV Chronic Lymphocytic Leukemia"
          ],
          "lead_sponsor": "National Cancer Institute (NCI)",
          "collaborators": [],
          "interventions": [
            "Bendamustine Hydrochloride",
            "Biospecimen Collection",
            "Bone Marrow Aspiration",
            "Bone Marrow Biopsy",
            "Computed Tomography",
            "Ibrutinib",
            "Laboratory Biomarker Analysis",
            "Quality-of-Life Assessment",
            "Rituximab"
          ],
          "last_update": "2025-11-28",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT01886872"
        },
        {
          "nct_id": "NCT04908228",
          "title": "Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Chronic Lymphocytic Leukemia"
          ],
          "lead_sponsor": "Paolo Ghia",
          "collaborators": [],
          "interventions": [
            "Ibrutinib and obinutuzumab"
          ],
          "last_update": "2023-10-03",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04908228"
        },
        {
          "nct_id": "NCT02268851",
          "title": "A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination With Ibrutinib in Patients With Select B-Cell Malignancies",
          "overall_status": "COMPLETED",
          "phase": "Phase 1",
          "conditions": [
            "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
            "Mantle Cell Lymphoma"
          ],
          "lead_sponsor": "Dana-Farber Cancer Institute",
          "collaborators": [
            "TG Therapeutics, Inc.",
            "The Leukemia and Lymphoma Society",
            "Blood Cancer Research Partnership"
          ],
          "interventions": [
            "TGR-1202",
            "Ibrutinib"
          ],
          "last_update": "2024-11-15",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02268851"
        },
        {
          "nct_id": "NCT02455297",
          "title": "A Single-arm, Open-label Phase IIa Study to Evaluate the Efficacy and Safety of Copanlisib Monotherapy in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL), Who Failed Ibrutinib Treatment or Were Unable to Tolerate Ibrutinib",
          "overall_status": "TERMINATED",
          "phase": "Phase 2",
          "conditions": [
            "Lymphoma, Mantle-Cell"
          ],
          "lead_sponsor": "Bayer",
          "collaborators": [],
          "interventions": [
            "Copanlisib (BAY80-6946)"
          ],
          "last_update": "2017-10-02",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02455297"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "IMBRUVICA (ibrutinib)",
        "ibrutinib",
        "IMBRUVICA"
      ]
    },
    {
      "asset": "INLEXZO (gemcitabine intravesical system)",
      "indication": "Non Muscle Invasive Bladder Cancer",
      "phase": null,
      "trial_or_program": "SunRISe-1",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT04658862",
          "title": "A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder Who Are Not Receiving Radical Cystectomy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Urinary Bladder Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Cetrelimab",
            "TAR-200",
            "Cisplatin",
            "Gemcitabine",
            "Conventional radiation therapy",
            "Hypo-fractioned radiation therapy"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04658862"
        },
        {
          "nct_id": "NCT06919965",
          "title": "A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Non-Muscle Invasive Bladder Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "TAR-210",
            "Mitomycin C",
            "Gemcitabine"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06919965"
        },
        {
          "nct_id": "NCT04640623",
          "title": "Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin (BCG) Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Urinary Bladder Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "TAR-200",
            "Cetrelimab"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04640623"
        },
        {
          "nct_id": "NCT04172675",
          "title": "A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Urinary Bladder Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Erdafitinib",
            "Investigator Choice (Gemcitabine)",
            "Investigator Choice (Mitomycin C)"
          ],
          "last_update": "2025-08-01",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04172675"
        },
        {
          "nct_id": "NCT03404791",
          "title": "A Multicenter Study Evaluating Safety and Efficacy of TAR-200 in Subjects With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy",
          "overall_status": "COMPLETED",
          "phase": "Phase 1",
          "conditions": [
            "Urinary Bladder Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "TAR-200"
          ],
          "last_update": "2025-02-04",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03404791"
        },
        {
          "nct_id": "NCT07322263",
          "title": "Intravesical Gemcitabine and Docetaxel for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: A Prospective Cohort Study (GEMDOCE-BU)",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Bladder Cancer",
            "Non-Muscle Invasive Bladder Cancer (NMIBC)",
            "Urothelial Carcinoma",
            "Carcinoma in Situ (CIS)",
            "High-Grade Papillary Bladder Tumors",
            "BCG-Unresponsive Bladder Cancer",
            "Ta Stage Bladder Cancer",
            "T1 Stage Bladder Cancer",
            "BCG-Refractory Bladder Cancer",
            "High-Risk NMIBC"
          ],
          "lead_sponsor": "Michael A. O'Donnell",
          "collaborators": [],
          "interventions": [
            "Intravesical Gemcitabine and Docetaxel"
          ],
          "last_update": "2026-01-07",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07322263"
        },
        {
          "nct_id": "NCT07307456",
          "title": "A Prospective, Open-label, Single-center Clinical Study Evaluating the Efficacy and Safety of Trastuzumab Combined With BCG Perfusion as an Adjuvant Treatment After TURBT in High-risk/Very High-risk Non-muscle-invasive Bladder Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Bladder Cancer"
          ],
          "lead_sponsor": "Changhai Hospital",
          "collaborators": [],
          "interventions": [
            "Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor (TURBT)"
          ],
          "last_update": "2025-12-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07307456"
        },
        {
          "nct_id": "NCT06545955",
          "title": "A Phase 3, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Non-muscle Invasive Bladder Cancer With Carcinoma in Situ"
          ],
          "lead_sponsor": "Ferring Pharmaceuticals",
          "collaborators": [],
          "interventions": [
            "Nadofaragene Firadenovec",
            "Gemcitabine",
            "Docetaxel",
            "Pembrolizumab"
          ],
          "last_update": "2026-01-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06545955"
        },
        {
          "nct_id": "NCT07000084",
          "title": "GAIN-BCG: Gemcitabine Alternating With INtravesical BCG Randomized Against BCG Alone for Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Recurrent Non-Muscle Invasive Bladder Carcinoma",
            "Stage 0a Bladder Cancer AJCC v8",
            "Stage I Bladder Cancer AJCC v8"
          ],
          "lead_sponsor": "Alliance for Clinical Trials in Oncology",
          "collaborators": [
            "National Cancer Institute (NCI)"
          ],
          "interventions": [
            "BCG Solution",
            "Biopsy of Bladder",
            "Cystoscopy",
            "Computed Tomography",
            "Magnetic Resonance Imaging",
            "Biospecimen Collection",
            "Transurethral Resection of Bladder Tumor",
            "Gemcitabine"
          ],
          "last_update": "2026-01-07",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07000084"
        },
        {
          "nct_id": "NCT05538663",
          "title": "A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Non-muscle-invasive Bladder Cancer"
          ],
          "lead_sponsor": "ECOG-ACRIN Cancer Research Group",
          "collaborators": [
            "National Cancer Institute (NCI)"
          ],
          "interventions": [
            "Gemcitabine",
            "Docetaxel",
            "Bacillus Calmette Guerin"
          ],
          "last_update": "2025-12-30",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05538663"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "INLEXZO (gemcitabine intravesical system)",
        "gemcitabine intravesical system",
        "INLEXZO"
      ]
    },
    {
      "asset": "RYBREVANT (amivantamab)",
      "indication": "Frontline Non Small Cell Lung Cancer in combination with chemotherapy",
      "phase": null,
      "trial_or_program": "PAPILLON",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT07276399",
          "title": "A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Squamous Cell Carcinoma of Head and Neck"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Pembrolizumab",
            "Carboplatin",
            "5-Flurouracil",
            "Cisplatin"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07276399"
        },
        {
          "nct_id": "NCT07227025",
          "title": "A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Olomorasib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07227025"
        },
        {
          "nct_id": "NCT05379595",
          "title": "A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Advanced or Metastatic Colorectal Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab IV",
            "Fluorouracil",
            "Leucovorin",
            "Oxaliplatin",
            "Irinotecan",
            "Amivantamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05379595"
        },
        {
          "nct_id": "NCT06662786",
          "title": "A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Colorectal Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Cetuximab",
            "5-fluorouracil",
            "Leucovorin calcium/Levoleucovorin",
            "Oxaliplatin",
            "Irinotecan Hydrochloride"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06662786"
        },
        {
          "nct_id": "NCT04965090",
          "title": "A Phase 2 Single-Arm Study of Amivantamab (JNJ-61186372) and Lazertinib in Metastatic EGFR-mutant Lung Cancer With Progressive or New CNS Metastases on Previous Treatment",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Metastatic Non Small Cell Lung Cancer",
            "Recurrent Non Small Cell Lung Cancer"
          ],
          "lead_sponsor": "Memorial Sloan Kettering Cancer Center",
          "collaborators": [
            "Janssen Scientific Affairs, LLC"
          ],
          "interventions": [
            "Amivantamab",
            "Lazertinib"
          ],
          "last_update": "2025-12-18",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04965090"
        },
        {
          "nct_id": "NCT04077463",
          "title": "An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Lazertinib",
            "Amivantamab",
            "Carboplatin",
            "Pemetrexed"
          ],
          "last_update": "2025-12-24",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04077463"
        },
        {
          "nct_id": "NCT06385080",
          "title": "A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Other Therapeutic Agents in Participants With Head and Neck Squamous Cell Carcinoma",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Squamous Cell Carcinoma of Head and Neck"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Pembrolizumab",
            "Paclitaxel",
            "Carboplatin"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06385080"
        },
        {
          "nct_id": "NCT04538664",
          "title": "A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Pemetrexed",
            "Carboplatin",
            "Pemetrexed"
          ],
          "last_update": "2025-12-23",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04538664"
        },
        {
          "nct_id": "NCT05498428",
          "title": "A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Carcinoma, Non-small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Lazertinib",
            "Carboplatin",
            "Pemetrexed",
            "Direct Oral Anticoagulant (DOAC)",
            "Low Molecular Weight Heparin (LMWH)"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05498428"
        },
        {
          "nct_id": "NCT05388669",
          "title": "A Phase 3, Open-label, Randomized Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Patients With EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Advanced or Metastatic Non-small Cell Lung Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Lazertinib",
            "Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)",
            "Amivantamab Intravenous"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05388669"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "RYBREVANT (amivantamab)",
        "amivantamab",
        "RYBREVANT"
      ]
    },
    {
      "asset": "RYBREVANT (amivantamab)",
      "indication": null,
      "phase": null,
      "trial_or_program": "PALOMA-3",
      "partner": null,
      "notes": "Subcutaneous",
      "_ctgov_matches": [
        {
          "nct_id": "NCT07276399",
          "title": "A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Squamous Cell Carcinoma of Head and Neck"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Pembrolizumab",
            "Carboplatin",
            "5-Flurouracil",
            "Cisplatin"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07276399"
        },
        {
          "nct_id": "NCT07227025",
          "title": "A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Olomorasib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07227025"
        },
        {
          "nct_id": "NCT05379595",
          "title": "A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Advanced or Metastatic Colorectal Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab IV",
            "Fluorouracil",
            "Leucovorin",
            "Oxaliplatin",
            "Irinotecan",
            "Amivantamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05379595"
        },
        {
          "nct_id": "NCT06662786",
          "title": "A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Colorectal Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Cetuximab",
            "5-fluorouracil",
            "Leucovorin calcium/Levoleucovorin",
            "Oxaliplatin",
            "Irinotecan Hydrochloride"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06662786"
        },
        {
          "nct_id": "NCT04965090",
          "title": "A Phase 2 Single-Arm Study of Amivantamab (JNJ-61186372) and Lazertinib in Metastatic EGFR-mutant Lung Cancer With Progressive or New CNS Metastases on Previous Treatment",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Metastatic Non Small Cell Lung Cancer",
            "Recurrent Non Small Cell Lung Cancer"
          ],
          "lead_sponsor": "Memorial Sloan Kettering Cancer Center",
          "collaborators": [
            "Janssen Scientific Affairs, LLC"
          ],
          "interventions": [
            "Amivantamab",
            "Lazertinib"
          ],
          "last_update": "2025-12-18",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04965090"
        },
        {
          "nct_id": "NCT04077463",
          "title": "An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Lazertinib",
            "Amivantamab",
            "Carboplatin",
            "Pemetrexed"
          ],
          "last_update": "2025-12-24",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04077463"
        },
        {
          "nct_id": "NCT06385080",
          "title": "A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Other Therapeutic Agents in Participants With Head and Neck Squamous Cell Carcinoma",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Squamous Cell Carcinoma of Head and Neck"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Pembrolizumab",
            "Paclitaxel",
            "Carboplatin"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06385080"
        },
        {
          "nct_id": "NCT04538664",
          "title": "A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Pemetrexed",
            "Carboplatin",
            "Pemetrexed"
          ],
          "last_update": "2025-12-23",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04538664"
        },
        {
          "nct_id": "NCT05498428",
          "title": "A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Carcinoma, Non-small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Lazertinib",
            "Carboplatin",
            "Pemetrexed",
            "Direct Oral Anticoagulant (DOAC)",
            "Low Molecular Weight Heparin (LMWH)"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05498428"
        },
        {
          "nct_id": "NCT05388669",
          "title": "A Phase 3, Open-label, Randomized Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Patients With EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Advanced or Metastatic Non-small Cell Lung Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Lazertinib",
            "Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)",
            "Amivantamab Intravenous"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05388669"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "RYBREVANT (amivantamab)",
        "amivantamab",
        "RYBREVANT"
      ]
    },
    {
      "asset": "Bleximenib",
      "indication": "Newly Diagnosed AML, chemo ineligible in combination with Venetoclax and Azacitidine",
      "phase": null,
      "trial_or_program": "cAMeLot-2",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT05453903",
          "title": "A Phase 1b Study of Bleximenib in Combination With AML-Directed Therapies for Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Leukemia, Myeloid, Acute"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Bleximenib",
            "Venetoclax (VEN)",
            "Azacitidine (AZA)",
            "Cytarabine",
            "Daunorubicin or Idarubicin"
          ],
          "last_update": "2025-12-24",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05453903"
        },
        {
          "nct_id": "NCT07295951",
          "title": "An Open-Label Study to Investigate the Absorption, Metabolism, And Excretion (AME) Of 14C-Bleximenib (JNJ-75276617) in Participants With Acute Leukemia",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Acute Lymphoblastic Leukemia",
            "Acute Leukemias",
            "Acute Myeloid Leukemia"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "14C-bleximenib",
            "bleximenib"
          ],
          "last_update": "2025-12-22",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07295951"
        },
        {
          "nct_id": "NCT06852222",
          "title": "A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Leukemia, Myeloid, Acute"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Bleximenib",
            "Venetoclax (VEN)",
            "Azacitidine (AZA)",
            "Placebo"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06852222"
        },
        {
          "nct_id": "NCT04811560",
          "title": "A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants With Acute Leukemia (cAMeLot-1)",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Acute Leukemias",
            "Acute Myeloid Leukemia",
            "Acute Lymphoblastic Leukemia"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Bleximenib"
          ],
          "last_update": "2025-12-10",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04811560"
        },
        {
          "nct_id": "NCT07223814",
          "title": "Bleximenib or Placebo in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for the Treatment of Patients With Newly Diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: a Double-blind Phase 3 Study",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Acute Myeloid Leukemia"
          ],
          "lead_sponsor": "Stichting Hemato-Oncologie voor Volwassenen Nederland",
          "collaborators": [
            "German-Austrian Acute Myeloid Leukemia Study Group"
          ],
          "interventions": [
            "Bleximenib",
            "Cytarabine",
            "Daunorubicin or Idarubicin",
            "Placebo"
          ],
          "last_update": "2025-11-03",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07223814"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "Bleximenib"
      ]
    },
    {
      "asset": "CARVYKTI (Ciltacabtagene autoleucel)",
      "indication": "Frontline Multiple Myeloma TNI",
      "phase": null,
      "trial_or_program": "CARTITUDE-5",
      "partner": "Legend Biotech",
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT06623630",
          "title": "A Pilot Safety and Feasibility Study of Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Washington University School of Medicine",
          "collaborators": [
            "American Cancer Society, Inc.",
            "Cures Within Reach"
          ],
          "interventions": [
            "Cyclophosphamide",
            "Ciltacabtagene Autoleucel",
            "Total body irradiation"
          ],
          "last_update": "2025-12-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06623630"
        },
        {
          "nct_id": "NCT05201781",
          "title": "Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Cilta-cel"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05201781"
        },
        {
          "nct_id": "NCT07149857",
          "title": "A Phase 2 Multicohort Trial to Further Characterize the Efficacy and Safety of Ciltacabtagene Autoleucel",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Cilta-cel",
            "Cyclophosphamide",
            "Induction therapy",
            "Fludarabine"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07149857"
        },
        {
          "nct_id": "NCT06577025",
          "title": "A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination With Daratumumab SC (Tal-D) and Teclistamab SC in Combination With Daratumumab SC (Tec-D) Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants With Standard-risk Newly Diagnosed Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Cilta-cel",
            "Talquetamab",
            "Daratumumab",
            "Teclistamab",
            "Bortezomib",
            "Lenalidomide",
            "Dexamethasone",
            "Cyclophosphamide",
            "Fludarabine"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06577025"
        },
        {
          "nct_id": "NCT04923893",
          "title": "A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Bortezomib",
            "Dexamethasone",
            "Lenalidomide",
            "Cilta-cel",
            "Cyclophosphamide",
            "Fludarabine"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04923893"
        },
        {
          "nct_id": "NCT05346835",
          "title": "Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma",
          "overall_status": "AVAILABLE",
          "phase": null,
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Scientific Affairs, LLC",
          "collaborators": [],
          "interventions": [
            "Cilta-cel OOS Therapy"
          ],
          "last_update": "2025-08-27",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05346835"
        },
        {
          "nct_id": "NCT05767359",
          "title": "CAR- PRISM (PRecision Intervention Smoldering Myeloma): A Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in High-Risk Smoldering Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma",
            "Smoldering Multiple Myeloma"
          ],
          "lead_sponsor": "Dana-Farber Cancer Institute",
          "collaborators": [
            "Janssen Research & Development, LLC"
          ],
          "interventions": [
            "Ciltacabtagene Autoleucel",
            "Cyclophosphamide",
            "Fludarabine Phosphate"
          ],
          "last_update": "2025-09-11",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05767359"
        },
        {
          "nct_id": "NCT05347485",
          "title": "A Safety and Efficacy Study of JNJ-68284528 (Ciltacabtagene Autoleucel) Out-of-Specification (OOS) for Commercial Release in Patients With Multiple Myeloma",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Scientific Affairs, LLC",
          "collaborators": [],
          "interventions": [
            "Cilta-cel",
            "Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)"
          ],
          "last_update": "2025-04-25",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05347485"
        },
        {
          "nct_id": "NCT07093554",
          "title": "Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Relapse Multiple Myeloma",
            "Refractory Multiple Myeloma"
          ],
          "lead_sponsor": "Medical College of Wisconsin",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Ciltacabtagene Autoleucel"
          ],
          "last_update": "2026-01-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07093554"
        },
        {
          "nct_id": "NCT03758417",
          "title": "A Phase 2, Open-Label Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA in Chinese Subjects With Relapsed or Refractory Multiple Myeloma",
          "overall_status": "TERMINATED",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Nanjing Legend Biotech Co.",
          "collaborators": [
            "Janssen Research & Development, LLC"
          ],
          "interventions": [
            "LCAR-B38M CAR-T Cell"
          ],
          "last_update": "2025-12-17",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03758417"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "CARVYKTI (Ciltacabtagene autoleucel)",
        "Ciltacabtagene autoleucel",
        "CARVYKTI"
      ]
    },
    {
      "asset": "CARVYKTI (Ciltacabtagene autoleucel)",
      "indication": "Frontline Multiple Myeloma Transplant Eligible vs ASCT",
      "phase": null,
      "trial_or_program": "CARTITUDE-6",
      "partner": "Legend Biotech",
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT06623630",
          "title": "A Pilot Safety and Feasibility Study of Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Washington University School of Medicine",
          "collaborators": [
            "American Cancer Society, Inc.",
            "Cures Within Reach"
          ],
          "interventions": [
            "Cyclophosphamide",
            "Ciltacabtagene Autoleucel",
            "Total body irradiation"
          ],
          "last_update": "2025-12-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06623630"
        },
        {
          "nct_id": "NCT05201781",
          "title": "Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Cilta-cel"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05201781"
        },
        {
          "nct_id": "NCT07149857",
          "title": "A Phase 2 Multicohort Trial to Further Characterize the Efficacy and Safety of Ciltacabtagene Autoleucel",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Cilta-cel",
            "Cyclophosphamide",
            "Induction therapy",
            "Fludarabine"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07149857"
        },
        {
          "nct_id": "NCT06577025",
          "title": "A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination With Daratumumab SC (Tal-D) and Teclistamab SC in Combination With Daratumumab SC (Tec-D) Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants With Standard-risk Newly Diagnosed Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Cilta-cel",
            "Talquetamab",
            "Daratumumab",
            "Teclistamab",
            "Bortezomib",
            "Lenalidomide",
            "Dexamethasone",
            "Cyclophosphamide",
            "Fludarabine"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06577025"
        },
        {
          "nct_id": "NCT04923893",
          "title": "A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Bortezomib",
            "Dexamethasone",
            "Lenalidomide",
            "Cilta-cel",
            "Cyclophosphamide",
            "Fludarabine"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04923893"
        },
        {
          "nct_id": "NCT05346835",
          "title": "Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma",
          "overall_status": "AVAILABLE",
          "phase": null,
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Scientific Affairs, LLC",
          "collaborators": [],
          "interventions": [
            "Cilta-cel OOS Therapy"
          ],
          "last_update": "2025-08-27",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05346835"
        },
        {
          "nct_id": "NCT05767359",
          "title": "CAR- PRISM (PRecision Intervention Smoldering Myeloma): A Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in High-Risk Smoldering Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma",
            "Smoldering Multiple Myeloma"
          ],
          "lead_sponsor": "Dana-Farber Cancer Institute",
          "collaborators": [
            "Janssen Research & Development, LLC"
          ],
          "interventions": [
            "Ciltacabtagene Autoleucel",
            "Cyclophosphamide",
            "Fludarabine Phosphate"
          ],
          "last_update": "2025-09-11",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05767359"
        },
        {
          "nct_id": "NCT05347485",
          "title": "A Safety and Efficacy Study of JNJ-68284528 (Ciltacabtagene Autoleucel) Out-of-Specification (OOS) for Commercial Release in Patients With Multiple Myeloma",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Scientific Affairs, LLC",
          "collaborators": [],
          "interventions": [
            "Cilta-cel",
            "Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)"
          ],
          "last_update": "2025-04-25",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05347485"
        },
        {
          "nct_id": "NCT07093554",
          "title": "Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Relapse Multiple Myeloma",
            "Refractory Multiple Myeloma"
          ],
          "lead_sponsor": "Medical College of Wisconsin",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Ciltacabtagene Autoleucel"
          ],
          "last_update": "2026-01-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07093554"
        },
        {
          "nct_id": "NCT03758417",
          "title": "A Phase 2, Open-Label Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA in Chinese Subjects With Relapsed or Refractory Multiple Myeloma",
          "overall_status": "TERMINATED",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Nanjing Legend Biotech Co.",
          "collaborators": [
            "Janssen Research & Development, LLC"
          ],
          "interventions": [
            "LCAR-B38M CAR-T Cell"
          ],
          "last_update": "2025-12-17",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03758417"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "CARVYKTI (Ciltacabtagene autoleucel)",
        "Ciltacabtagene autoleucel",
        "CARVYKTI"
      ]
    },
    {
      "asset": "ERLEADA (apalutamide)",
      "indication": "Localized Prostate Cancer",
      "phase": null,
      "trial_or_program": "ATLAS",
      "partner": "Regents of California and Memorial Sload Kettering",
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT07002320",
          "title": "ASpiRE: A Proof-of-mechanism and Proof-of-concept Clinical Trial Evaluating the Safety, Tolerability, Biological and Anti-tumour Activity of Apalutamide With Dual CXCR1 and CXCR2 Blockade by SX-682 for Men Suffering From Metastatic Castration-resistant Prostate Cancer (mCRPC)",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Metastatic Castrate-Resistant Prostate Cancer (mCRPC)"
          ],
          "lead_sponsor": "Institute of Cancer Research, United Kingdom",
          "collaborators": [
            "Prostate Cancer UK",
            "Janssen Pharmaceutica N.V., Belgium",
            "Oncology Institute of Southern Switzerland",
            "Syntrix Biosystems, Inc.",
            "Royal Marsden NHS Foundation Trust",
            "Cambridge University Hospitals NHS Foundation Trust",
            "Belfast Health and Social Care Trust",
            "Institute of Oncology Research (IOR)"
          ],
          "interventions": [
            "SX-682",
            "Apalutamide"
          ],
          "last_update": "2025-12-04",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07002320"
        },
        {
          "nct_id": "NCT03767244",
          "title": "A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Prostatic Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Apalutamide",
            "Androgen Deprivation Therapy (ADT)",
            "Placebo"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03767244"
        },
        {
          "nct_id": "NCT04523207",
          "title": "A Multi-center, Open-label, Single-arm Phase 2 Study of the Adjuvant Treatment of Apalutamide and Androgen Deprivation Therapy (ADT) in Treatment-naïve Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Prostatic Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Apalutamide",
            "ADT",
            "Relugolix"
          ],
          "last_update": "2025-04-25",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04523207"
        },
        {
          "nct_id": "NCT03802682",
          "title": "A Randomized, Open-label, Two-way, Crossover Study to Evaluate the Relative Bioavailability of Apalutamide Administered Orally as Whole Tablets and as a Mixture in Applesauce in Healthy Subjects",
          "overall_status": "COMPLETED",
          "phase": "Phase 1",
          "conditions": [
            "Healthy"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Apalutamide"
          ],
          "last_update": "2025-02-03",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03802682"
        },
        {
          "nct_id": "NCT04181203",
          "title": "An Open Label, Randomized, Phase III Study, Evaluating the Efficacy of a Combination of Apalutamide With Radiotherapy and LHRH Agonist in High-risk Postprostatectomy Biochemically Relapsed Prostate Cancer Patients",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Prostate Cancer"
          ],
          "lead_sponsor": "UNICANCER",
          "collaborators": [
            "Janssen Pharmaceutica"
          ],
          "interventions": [
            "Apalutamide",
            "Salvage radiotherapy (SRT)",
            "Luteinising Hormone Releasing Hormone agonist (LHRHa)"
          ],
          "last_update": "2025-07-30",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04181203"
        },
        {
          "nct_id": "NCT03903835",
          "title": "ProBio: An Outcome-adaptive and Randomized Multi-arm Biomarker Driven Study in Patients With Metastatic Prostate Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Metastatic Castration-resistant Prostate Cancer (mCRPC)",
            "Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)"
          ],
          "lead_sponsor": "Karolinska Institutet",
          "collaborators": [
            "The Swedish Research Council",
            "Kom Op Tegen Kanker",
            "Janssen Pharmaceutica N.V., Belgium",
            "AstraZeneca",
            "Cancerfonden"
          ],
          "interventions": [
            "Enzalutamide Oral Capsule",
            "Abiraterone Oral Tablet",
            "Carboplatin",
            "Cabazitaxel 60 mg Solution for Injection",
            "Docetaxel Injectable Solution",
            "Radium Chloride Ra-223",
            "Niraparib plus Abiraterone acetate plus Prednisone",
            "Capivasertib plus Docetaxel",
            "Apalutamide",
            "Darolutamide"
          ],
          "last_update": "2025-04-09",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03903835"
        },
        {
          "nct_id": "NCT05683964",
          "title": "Understanding the Interaction Between Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Prostate Adenocarcinoma",
            "Prostate Cancer",
            "Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)"
          ],
          "lead_sponsor": "Beth Israel Deaconess Medical Center",
          "collaborators": [
            "Dana-Farber Cancer Institute"
          ],
          "interventions": [
            "Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]",
            "Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan"
          ],
          "last_update": "2024-08-16",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05683964"
        },
        {
          "nct_id": "NCT02903368",
          "title": "Phase II Randomized Study Of Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide For Intermediate-High Risk Prostate Cancer Undergoing Prostatectomy",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Prostate Cancer"
          ],
          "lead_sponsor": "Dana-Farber Cancer Institute",
          "collaborators": [
            "Janssen Scientific Affairs, LLC"
          ],
          "interventions": [
            "Apalutamide",
            "Leuprolide",
            "Prednisone",
            "Abiraterone Acetate"
          ],
          "last_update": "2025-06-13",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02903368"
        },
        {
          "nct_id": "NCT02531516",
          "title": "ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Prostatic Neoplasms"
          ],
          "lead_sponsor": "Aragon Pharmaceuticals, Inc.",
          "collaborators": [],
          "interventions": [
            "Apalutamide",
            "Bicalutamide",
            "Bicalutamide Placebo",
            "Apalutamide Placebo",
            "GnRH (agonist)",
            "74-80 Grays (units of radiation)"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02531516"
        },
        {
          "nct_id": "NCT03569280",
          "title": "A First-in-Human Study to Determine the Safety, Pharmacokinetics and Efficacy of KPG-121 When Administered With Enzalutamide, Abiraterone, or Apalutamide in Subjects With Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer",
          "overall_status": "COMPLETED",
          "phase": "Phase 1",
          "conditions": [
            "Castration-Resistant Prostate Cancer"
          ],
          "lead_sponsor": "Kangpu Biopharmaceuticals, Ltd.",
          "collaborators": [],
          "interventions": [
            "Enzalutamide or Abiraterone or Apalutamid"
          ],
          "last_update": "2023-07-18",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03569280"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "ERLEADA (apalutamide)",
        "apalutamide",
        "ERLEADA"
      ]
    },
    {
      "asset": "ERLEADA (apalutamide)",
      "indication": "High Risk Prostate Cancer",
      "phase": null,
      "trial_or_program": "PROTEUS",
      "partner": "Regents of California and Memorial Sload Kettering",
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT07002320",
          "title": "ASpiRE: A Proof-of-mechanism and Proof-of-concept Clinical Trial Evaluating the Safety, Tolerability, Biological and Anti-tumour Activity of Apalutamide With Dual CXCR1 and CXCR2 Blockade by SX-682 for Men Suffering From Metastatic Castration-resistant Prostate Cancer (mCRPC)",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Metastatic Castrate-Resistant Prostate Cancer (mCRPC)"
          ],
          "lead_sponsor": "Institute of Cancer Research, United Kingdom",
          "collaborators": [
            "Prostate Cancer UK",
            "Janssen Pharmaceutica N.V., Belgium",
            "Oncology Institute of Southern Switzerland",
            "Syntrix Biosystems, Inc.",
            "Royal Marsden NHS Foundation Trust",
            "Cambridge University Hospitals NHS Foundation Trust",
            "Belfast Health and Social Care Trust",
            "Institute of Oncology Research (IOR)"
          ],
          "interventions": [
            "SX-682",
            "Apalutamide"
          ],
          "last_update": "2025-12-04",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07002320"
        },
        {
          "nct_id": "NCT03767244",
          "title": "A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Prostatic Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Apalutamide",
            "Androgen Deprivation Therapy (ADT)",
            "Placebo"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03767244"
        },
        {
          "nct_id": "NCT04523207",
          "title": "A Multi-center, Open-label, Single-arm Phase 2 Study of the Adjuvant Treatment of Apalutamide and Androgen Deprivation Therapy (ADT) in Treatment-naïve Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Prostatic Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Apalutamide",
            "ADT",
            "Relugolix"
          ],
          "last_update": "2025-04-25",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04523207"
        },
        {
          "nct_id": "NCT03802682",
          "title": "A Randomized, Open-label, Two-way, Crossover Study to Evaluate the Relative Bioavailability of Apalutamide Administered Orally as Whole Tablets and as a Mixture in Applesauce in Healthy Subjects",
          "overall_status": "COMPLETED",
          "phase": "Phase 1",
          "conditions": [
            "Healthy"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Apalutamide"
          ],
          "last_update": "2025-02-03",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03802682"
        },
        {
          "nct_id": "NCT04181203",
          "title": "An Open Label, Randomized, Phase III Study, Evaluating the Efficacy of a Combination of Apalutamide With Radiotherapy and LHRH Agonist in High-risk Postprostatectomy Biochemically Relapsed Prostate Cancer Patients",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Prostate Cancer"
          ],
          "lead_sponsor": "UNICANCER",
          "collaborators": [
            "Janssen Pharmaceutica"
          ],
          "interventions": [
            "Apalutamide",
            "Salvage radiotherapy (SRT)",
            "Luteinising Hormone Releasing Hormone agonist (LHRHa)"
          ],
          "last_update": "2025-07-30",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04181203"
        },
        {
          "nct_id": "NCT03903835",
          "title": "ProBio: An Outcome-adaptive and Randomized Multi-arm Biomarker Driven Study in Patients With Metastatic Prostate Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Metastatic Castration-resistant Prostate Cancer (mCRPC)",
            "Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)"
          ],
          "lead_sponsor": "Karolinska Institutet",
          "collaborators": [
            "The Swedish Research Council",
            "Kom Op Tegen Kanker",
            "Janssen Pharmaceutica N.V., Belgium",
            "AstraZeneca",
            "Cancerfonden"
          ],
          "interventions": [
            "Enzalutamide Oral Capsule",
            "Abiraterone Oral Tablet",
            "Carboplatin",
            "Cabazitaxel 60 mg Solution for Injection",
            "Docetaxel Injectable Solution",
            "Radium Chloride Ra-223",
            "Niraparib plus Abiraterone acetate plus Prednisone",
            "Capivasertib plus Docetaxel",
            "Apalutamide",
            "Darolutamide"
          ],
          "last_update": "2025-04-09",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03903835"
        },
        {
          "nct_id": "NCT05683964",
          "title": "Understanding the Interaction Between Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Prostate Adenocarcinoma",
            "Prostate Cancer",
            "Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)"
          ],
          "lead_sponsor": "Beth Israel Deaconess Medical Center",
          "collaborators": [
            "Dana-Farber Cancer Institute"
          ],
          "interventions": [
            "Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]",
            "Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan"
          ],
          "last_update": "2024-08-16",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05683964"
        },
        {
          "nct_id": "NCT02903368",
          "title": "Phase II Randomized Study Of Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide For Intermediate-High Risk Prostate Cancer Undergoing Prostatectomy",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Prostate Cancer"
          ],
          "lead_sponsor": "Dana-Farber Cancer Institute",
          "collaborators": [
            "Janssen Scientific Affairs, LLC"
          ],
          "interventions": [
            "Apalutamide",
            "Leuprolide",
            "Prednisone",
            "Abiraterone Acetate"
          ],
          "last_update": "2025-06-13",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02903368"
        },
        {
          "nct_id": "NCT02531516",
          "title": "ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Prostatic Neoplasms"
          ],
          "lead_sponsor": "Aragon Pharmaceuticals, Inc.",
          "collaborators": [],
          "interventions": [
            "Apalutamide",
            "Bicalutamide",
            "Bicalutamide Placebo",
            "Apalutamide Placebo",
            "GnRH (agonist)",
            "74-80 Grays (units of radiation)"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02531516"
        },
        {
          "nct_id": "NCT03569280",
          "title": "A First-in-Human Study to Determine the Safety, Pharmacokinetics and Efficacy of KPG-121 When Administered With Enzalutamide, Abiraterone, or Apalutamide in Subjects With Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer",
          "overall_status": "COMPLETED",
          "phase": "Phase 1",
          "conditions": [
            "Castration-Resistant Prostate Cancer"
          ],
          "lead_sponsor": "Kangpu Biopharmaceuticals, Ltd.",
          "collaborators": [],
          "interventions": [
            "Enzalutamide or Abiraterone or Apalutamid"
          ],
          "last_update": "2023-07-18",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03569280"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "ERLEADA (apalutamide)",
        "apalutamide",
        "ERLEADA"
      ]
    },
    {
      "asset": "INLEXZO (gemcitabine intravesical system)",
      "indication": "Non Muscle Invasive Bladder Cancer BCG-naïve High Risk",
      "phase": null,
      "trial_or_program": "SunRISe-3",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT04658862",
          "title": "A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder Who Are Not Receiving Radical Cystectomy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Urinary Bladder Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Cetrelimab",
            "TAR-200",
            "Cisplatin",
            "Gemcitabine",
            "Conventional radiation therapy",
            "Hypo-fractioned radiation therapy"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04658862"
        },
        {
          "nct_id": "NCT06919965",
          "title": "A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Non-Muscle Invasive Bladder Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "TAR-210",
            "Mitomycin C",
            "Gemcitabine"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06919965"
        },
        {
          "nct_id": "NCT04640623",
          "title": "Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin (BCG) Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Urinary Bladder Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "TAR-200",
            "Cetrelimab"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04640623"
        },
        {
          "nct_id": "NCT04172675",
          "title": "A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Urinary Bladder Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Erdafitinib",
            "Investigator Choice (Gemcitabine)",
            "Investigator Choice (Mitomycin C)"
          ],
          "last_update": "2025-08-01",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04172675"
        },
        {
          "nct_id": "NCT03404791",
          "title": "A Multicenter Study Evaluating Safety and Efficacy of TAR-200 in Subjects With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy",
          "overall_status": "COMPLETED",
          "phase": "Phase 1",
          "conditions": [
            "Urinary Bladder Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "TAR-200"
          ],
          "last_update": "2025-02-04",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03404791"
        },
        {
          "nct_id": "NCT07322263",
          "title": "Intravesical Gemcitabine and Docetaxel for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: A Prospective Cohort Study (GEMDOCE-BU)",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Bladder Cancer",
            "Non-Muscle Invasive Bladder Cancer (NMIBC)",
            "Urothelial Carcinoma",
            "Carcinoma in Situ (CIS)",
            "High-Grade Papillary Bladder Tumors",
            "BCG-Unresponsive Bladder Cancer",
            "Ta Stage Bladder Cancer",
            "T1 Stage Bladder Cancer",
            "BCG-Refractory Bladder Cancer",
            "High-Risk NMIBC"
          ],
          "lead_sponsor": "Michael A. O'Donnell",
          "collaborators": [],
          "interventions": [
            "Intravesical Gemcitabine and Docetaxel"
          ],
          "last_update": "2026-01-07",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07322263"
        },
        {
          "nct_id": "NCT07307456",
          "title": "A Prospective, Open-label, Single-center Clinical Study Evaluating the Efficacy and Safety of Trastuzumab Combined With BCG Perfusion as an Adjuvant Treatment After TURBT in High-risk/Very High-risk Non-muscle-invasive Bladder Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Bladder Cancer"
          ],
          "lead_sponsor": "Changhai Hospital",
          "collaborators": [],
          "interventions": [
            "Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor (TURBT)"
          ],
          "last_update": "2025-12-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07307456"
        },
        {
          "nct_id": "NCT06545955",
          "title": "A Phase 3, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Non-muscle Invasive Bladder Cancer With Carcinoma in Situ"
          ],
          "lead_sponsor": "Ferring Pharmaceuticals",
          "collaborators": [],
          "interventions": [
            "Nadofaragene Firadenovec",
            "Gemcitabine",
            "Docetaxel",
            "Pembrolizumab"
          ],
          "last_update": "2026-01-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06545955"
        },
        {
          "nct_id": "NCT07000084",
          "title": "GAIN-BCG: Gemcitabine Alternating With INtravesical BCG Randomized Against BCG Alone for Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Recurrent Non-Muscle Invasive Bladder Carcinoma",
            "Stage 0a Bladder Cancer AJCC v8",
            "Stage I Bladder Cancer AJCC v8"
          ],
          "lead_sponsor": "Alliance for Clinical Trials in Oncology",
          "collaborators": [
            "National Cancer Institute (NCI)"
          ],
          "interventions": [
            "BCG Solution",
            "Biopsy of Bladder",
            "Cystoscopy",
            "Computed Tomography",
            "Magnetic Resonance Imaging",
            "Biospecimen Collection",
            "Transurethral Resection of Bladder Tumor",
            "Gemcitabine"
          ],
          "last_update": "2026-01-07",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07000084"
        },
        {
          "nct_id": "NCT05538663",
          "title": "A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Non-muscle-invasive Bladder Cancer"
          ],
          "lead_sponsor": "ECOG-ACRIN Cancer Research Group",
          "collaborators": [
            "National Cancer Institute (NCI)"
          ],
          "interventions": [
            "Gemcitabine",
            "Docetaxel",
            "Bacillus Calmette Guerin"
          ],
          "last_update": "2025-12-30",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05538663"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "INLEXZO (gemcitabine intravesical system)",
        "gemcitabine intravesical system",
        "INLEXZO"
      ]
    },
    {
      "asset": "INLEXZO (gemcitabine intravesical system)",
      "indication": "High Risk Non Muscle Invasive Bladder Cancer BGC Experienced",
      "phase": null,
      "trial_or_program": "SunRISe-5",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT04658862",
          "title": "A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder Who Are Not Receiving Radical Cystectomy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Urinary Bladder Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Cetrelimab",
            "TAR-200",
            "Cisplatin",
            "Gemcitabine",
            "Conventional radiation therapy",
            "Hypo-fractioned radiation therapy"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04658862"
        },
        {
          "nct_id": "NCT06919965",
          "title": "A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Non-Muscle Invasive Bladder Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "TAR-210",
            "Mitomycin C",
            "Gemcitabine"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06919965"
        },
        {
          "nct_id": "NCT04640623",
          "title": "Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin (BCG) Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Urinary Bladder Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "TAR-200",
            "Cetrelimab"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04640623"
        },
        {
          "nct_id": "NCT04172675",
          "title": "A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Urinary Bladder Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Erdafitinib",
            "Investigator Choice (Gemcitabine)",
            "Investigator Choice (Mitomycin C)"
          ],
          "last_update": "2025-08-01",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04172675"
        },
        {
          "nct_id": "NCT03404791",
          "title": "A Multicenter Study Evaluating Safety and Efficacy of TAR-200 in Subjects With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy",
          "overall_status": "COMPLETED",
          "phase": "Phase 1",
          "conditions": [
            "Urinary Bladder Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "TAR-200"
          ],
          "last_update": "2025-02-04",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03404791"
        },
        {
          "nct_id": "NCT07322263",
          "title": "Intravesical Gemcitabine and Docetaxel for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: A Prospective Cohort Study (GEMDOCE-BU)",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Bladder Cancer",
            "Non-Muscle Invasive Bladder Cancer (NMIBC)",
            "Urothelial Carcinoma",
            "Carcinoma in Situ (CIS)",
            "High-Grade Papillary Bladder Tumors",
            "BCG-Unresponsive Bladder Cancer",
            "Ta Stage Bladder Cancer",
            "T1 Stage Bladder Cancer",
            "BCG-Refractory Bladder Cancer",
            "High-Risk NMIBC"
          ],
          "lead_sponsor": "Michael A. O'Donnell",
          "collaborators": [],
          "interventions": [
            "Intravesical Gemcitabine and Docetaxel"
          ],
          "last_update": "2026-01-07",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07322263"
        },
        {
          "nct_id": "NCT07307456",
          "title": "A Prospective, Open-label, Single-center Clinical Study Evaluating the Efficacy and Safety of Trastuzumab Combined With BCG Perfusion as an Adjuvant Treatment After TURBT in High-risk/Very High-risk Non-muscle-invasive Bladder Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Bladder Cancer"
          ],
          "lead_sponsor": "Changhai Hospital",
          "collaborators": [],
          "interventions": [
            "Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor (TURBT)"
          ],
          "last_update": "2025-12-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07307456"
        },
        {
          "nct_id": "NCT06545955",
          "title": "A Phase 3, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Non-muscle Invasive Bladder Cancer With Carcinoma in Situ"
          ],
          "lead_sponsor": "Ferring Pharmaceuticals",
          "collaborators": [],
          "interventions": [
            "Nadofaragene Firadenovec",
            "Gemcitabine",
            "Docetaxel",
            "Pembrolizumab"
          ],
          "last_update": "2026-01-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06545955"
        },
        {
          "nct_id": "NCT07000084",
          "title": "GAIN-BCG: Gemcitabine Alternating With INtravesical BCG Randomized Against BCG Alone for Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Recurrent Non-Muscle Invasive Bladder Carcinoma",
            "Stage 0a Bladder Cancer AJCC v8",
            "Stage I Bladder Cancer AJCC v8"
          ],
          "lead_sponsor": "Alliance for Clinical Trials in Oncology",
          "collaborators": [
            "National Cancer Institute (NCI)"
          ],
          "interventions": [
            "BCG Solution",
            "Biopsy of Bladder",
            "Cystoscopy",
            "Computed Tomography",
            "Magnetic Resonance Imaging",
            "Biospecimen Collection",
            "Transurethral Resection of Bladder Tumor",
            "Gemcitabine"
          ],
          "last_update": "2026-01-07",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07000084"
        },
        {
          "nct_id": "NCT05538663",
          "title": "A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Non-muscle-invasive Bladder Cancer"
          ],
          "lead_sponsor": "ECOG-ACRIN Cancer Research Group",
          "collaborators": [
            "National Cancer Institute (NCI)"
          ],
          "interventions": [
            "Gemcitabine",
            "Docetaxel",
            "Bacillus Calmette Guerin"
          ],
          "last_update": "2025-12-30",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05538663"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "INLEXZO (gemcitabine intravesical system)",
        "gemcitabine intravesical system",
        "INLEXZO"
      ]
    },
    {
      "asset": "JNJ-1900 (NBTXR3)",
      "indication": "Head and Neck Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": "Nanobiotix",
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT04892173",
          "title": "A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With LA-HNSCC",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Locally Advanced Head and Neck Squamous Cell Carcinoma",
            "Aged"
          ],
          "lead_sponsor": "Johnson & Johnson Enterprise Innovation Inc.",
          "collaborators": [],
          "interventions": [
            "JNJ-90301900 (NBTXR3)",
            "Cetuximab",
            "Radiation Therapy"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04892173"
        },
        {
          "nct_id": "NCT07224152",
          "title": "NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Locally-Advanced Non-Small Cell Lung Cancer"
          ],
          "lead_sponsor": "M.D. Anderson Cancer Center",
          "collaborators": [
            "Nanobiotix"
          ],
          "interventions": [
            "NBTXR3"
          ],
          "last_update": "2025-12-16",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07224152"
        },
        {
          "nct_id": "NCT04862455",
          "title": "Phase II Study of NBTXR3 Activated by Radiation and Combined With Pembrolizumab for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma With Limited PD-L1 Expression or Refractory to PD-1 Blockade",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Metastatic Head and Neck Squamous Cell Carcinoma",
            "Recurrent Head and Neck Squamous Cell Carcinoma"
          ],
          "lead_sponsor": "M.D. Anderson Cancer Center",
          "collaborators": [],
          "interventions": [
            "Hafnium Oxide-containing Nanoparticles NBTXR3",
            "Hypofractionated Radiation Therapy",
            "Pembrolizumab",
            "Stereotactic Body Radiation Therapy"
          ],
          "last_update": "2025-11-21",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04862455"
        },
        {
          "nct_id": "NCT07219212",
          "title": "A Study of JNJ-90301900 in Combination With Concurrent Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Squamous Cell Carcinoma of Head and Neck"
          ],
          "lead_sponsor": "Johnson & Johnson Enterprise Innovation Inc.",
          "collaborators": [],
          "interventions": [
            "JNJ-90301900",
            "Cisplatin",
            "Intensity Modulated Radiation Therapy (IMRT)"
          ],
          "last_update": "2025-12-24",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07219212"
        },
        {
          "nct_id": "NCT05039632",
          "title": "Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Advanced Malignant Solid Neoplasm",
            "Metastatic Malignant Neoplasm in the Liver",
            "Metastatic Malignant Neoplasm in the Lung",
            "Metastatic Malignant Solid Neoplasm"
          ],
          "lead_sponsor": "M.D. Anderson Cancer Center",
          "collaborators": [
            "National Cancer Institute (NCI)"
          ],
          "interventions": [
            "Hafnium Oxide-containing Nanoparticles NBTXR3",
            "Radiation Therapy",
            "Radiation Therapy"
          ],
          "last_update": "2025-11-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05039632"
        },
        {
          "nct_id": "NCT02379845",
          "title": "A Multicenter Randomized, Open-Label Phase II/III Study, To Compare The Efficacy Of NBTXR3, Implanted As Intratumor Injection And Activated By Radiotherapy, Versus Radiotherapy Alone In Patients With Locally Advanced Soft Tissue Sarcoma Of The Extremity And Trunk Wall",
          "overall_status": "COMPLETED",
          "phase": "Phase 3",
          "conditions": [
            "Adult Soft Tissue Sarcoma"
          ],
          "lead_sponsor": "Nanobiotix",
          "collaborators": [
            "PharmaEngine"
          ],
          "interventions": [
            "NBTXR3",
            "Radiation therapy"
          ],
          "last_update": "2021-04-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02379845"
        },
        {
          "nct_id": "NCT04615013",
          "title": "A Phase 1 Study of NBTXR3 Activated by Radiotherapy With Concurrent Chemotherapy for Adenocarcinoma of the Esophagus",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Cervical Esophagus Adenocarcinoma",
            "Clinical Stage II Esophageal Adenocarcinoma AJCC v8",
            "Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8",
            "Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8",
            "Clinical Stage III Esophageal Adenocarcinoma AJCC v8",
            "Gastroesophageal Junction Adenocarcinoma",
            "Pathologic Stage II Esophageal Adenocarcinoma AJCC v8",
            "Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8",
            "Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8",
            "Pathologic Stage III Esophageal Adenocarcinoma AJCC v8"
          ],
          "lead_sponsor": "M.D. Anderson Cancer Center",
          "collaborators": [
            "National Cancer Institute (NCI)"
          ],
          "interventions": [
            "Capecitabine",
            "Carboplatin",
            "Docetaxel",
            "Fluorouracil",
            "Hafnium Oxide-containing Nanoparticles NBTXR3",
            "Intensity-Modulated Radiation Therapy",
            "Leucovorin",
            "Oxaliplatin",
            "Paclitaxel"
          ],
          "last_update": "2025-10-30",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04615013"
        },
        {
          "nct_id": "NCT04484909",
          "title": "Phase I Study of NBTXR3 Activated by Radiotherapy for Locally Advanced or Borderline Resectable Pancreatic Ductal Adenocarcinoma",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Borderline Resectable Pancreatic Adenocarcinoma",
            "Locally Advanced Pancreatic Ductal Adenocarcinoma",
            "Resectable Pancreatic Ductal Adenocarcinoma",
            "Stage III Pancreatic Cancer AJCC v8"
          ],
          "lead_sponsor": "M.D. Anderson Cancer Center",
          "collaborators": [
            "National Cancer Institute (NCI)"
          ],
          "interventions": [
            "Hafnium Oxide-containing Nanoparticles NBTXR3",
            "Radiation Therapy"
          ],
          "last_update": "2025-10-27",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04484909"
        },
        {
          "nct_id": "NCT01433068",
          "title": "An Open-Label, Single Arm, Feasibility And Safety Phase I Study With NBTXR3 Intratumor Implantation (By Injection) And Activated By External Beam Radiation Therapy In Patients With Soft Tissue Sarcoma Of The Extremity And Trunk Wall",
          "overall_status": "COMPLETED",
          "phase": "Phase 1",
          "conditions": [
            "Adult Soft Tissue Sarcoma"
          ],
          "lead_sponsor": "Nanobiotix",
          "collaborators": [],
          "interventions": [
            "NBTXR3"
          ],
          "last_update": "2020-10-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT01433068"
        },
        {
          "nct_id": "NCT04834349",
          "title": "A Phase II Study of Reirradiation With NBTXR3 in Patients With Inoperable Locoregional Recurrent Head and Neck Squamous Cell Carcinoma",
          "overall_status": "WITHDRAWN",
          "phase": "Phase 2",
          "conditions": [
            "Recurrent Head and Neck Squamous Cell Carcinoma",
            "Unresectable Head and Neck Squamous Cell Carcinoma"
          ],
          "lead_sponsor": "M.D. Anderson Cancer Center",
          "collaborators": [],
          "interventions": [
            "Hafnium Oxide-containing Nanoparticles NBTXR3",
            "Intensity-Modulated Proton Therapy",
            "Intensity-Modulated Radiation Therapy",
            "Pembrolizumab",
            "Quality-of-Life Assessment",
            "Questionnaire Administration",
            "Stereotactic Body Radiation Therapy"
          ],
          "last_update": "2023-09-13",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04834349"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "JNJ-1900 (NBTXR3)",
        "NBTXR3",
        "JNJ-1900"
      ]
    },
    {
      "asset": "pasritamig",
      "indication": "Prostate Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT07319871",
          "title": "A Phase 1b Study of Pasritamig (JNJ-78278343), a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With JNJ-86974680, an A2a Receptor (A2aR) Antagonist, for Prostate Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Prostatic Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Pasritamig",
            "JNJ-86974680"
          ],
          "last_update": "2026-01-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07319871"
        },
        {
          "nct_id": "NCT07225946",
          "title": "A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Prostatic Neoplasms, Castration-Resistant"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Pasritamig",
            "Docetaxel",
            "Prednisone"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07225946"
        },
        {
          "nct_id": "NCT07164443",
          "title": "A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T Cell Redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Metastatic Castration-resistant Prostate Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Pasritamig",
            "Placebo",
            "Best Supportive Care (BSC)"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07164443"
        },
        {
          "nct_id": "NCT06095089",
          "title": "A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody) Combined With JNJ-78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Advanced Prostate Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "JNJ-78278343",
            "JNJ-87189401"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06095089"
        },
        {
          "nct_id": "NCT07082920",
          "title": "A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With JNJ-95298177, an Antibody Drug Conjugate Targeting Prostate Specific Membrane Antigen, for Prostate Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Prostatic Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "JNJ-78278343",
            "JNJ-95298177"
          ],
          "last_update": "2025-12-17",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07082920"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "pasritamig"
      ]
    },
    {
      "asset": "RYBREVANT (amivantamab)",
      "indication": "Colorectal Cancer",
      "phase": null,
      "trial_or_program": "ORIGAMI-2",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT07276399",
          "title": "A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Squamous Cell Carcinoma of Head and Neck"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Pembrolizumab",
            "Carboplatin",
            "5-Flurouracil",
            "Cisplatin"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07276399"
        },
        {
          "nct_id": "NCT07227025",
          "title": "A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Olomorasib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07227025"
        },
        {
          "nct_id": "NCT05379595",
          "title": "A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Advanced or Metastatic Colorectal Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab IV",
            "Fluorouracil",
            "Leucovorin",
            "Oxaliplatin",
            "Irinotecan",
            "Amivantamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05379595"
        },
        {
          "nct_id": "NCT06662786",
          "title": "A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Colorectal Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Cetuximab",
            "5-fluorouracil",
            "Leucovorin calcium/Levoleucovorin",
            "Oxaliplatin",
            "Irinotecan Hydrochloride"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06662786"
        },
        {
          "nct_id": "NCT04965090",
          "title": "A Phase 2 Single-Arm Study of Amivantamab (JNJ-61186372) and Lazertinib in Metastatic EGFR-mutant Lung Cancer With Progressive or New CNS Metastases on Previous Treatment",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Metastatic Non Small Cell Lung Cancer",
            "Recurrent Non Small Cell Lung Cancer"
          ],
          "lead_sponsor": "Memorial Sloan Kettering Cancer Center",
          "collaborators": [
            "Janssen Scientific Affairs, LLC"
          ],
          "interventions": [
            "Amivantamab",
            "Lazertinib"
          ],
          "last_update": "2025-12-18",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04965090"
        },
        {
          "nct_id": "NCT04077463",
          "title": "An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Lazertinib",
            "Amivantamab",
            "Carboplatin",
            "Pemetrexed"
          ],
          "last_update": "2025-12-24",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04077463"
        },
        {
          "nct_id": "NCT06385080",
          "title": "A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Other Therapeutic Agents in Participants With Head and Neck Squamous Cell Carcinoma",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Squamous Cell Carcinoma of Head and Neck"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Pembrolizumab",
            "Paclitaxel",
            "Carboplatin"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06385080"
        },
        {
          "nct_id": "NCT04538664",
          "title": "A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Pemetrexed",
            "Carboplatin",
            "Pemetrexed"
          ],
          "last_update": "2025-12-23",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04538664"
        },
        {
          "nct_id": "NCT05498428",
          "title": "A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Carcinoma, Non-small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Lazertinib",
            "Carboplatin",
            "Pemetrexed",
            "Direct Oral Anticoagulant (DOAC)",
            "Low Molecular Weight Heparin (LMWH)"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05498428"
        },
        {
          "nct_id": "NCT05388669",
          "title": "A Phase 3, Open-label, Randomized Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Patients With EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Advanced or Metastatic Non-small Cell Lung Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Lazertinib",
            "Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)",
            "Amivantamab Intravenous"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05388669"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "RYBREVANT (amivantamab)",
        "amivantamab",
        "RYBREVANT"
      ]
    },
    {
      "asset": "RYBREVANT (amivantamab)",
      "indication": "Colorectal Cancer 2L",
      "phase": null,
      "trial_or_program": "ORIGAMI-3",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT07276399",
          "title": "A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Squamous Cell Carcinoma of Head and Neck"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Pembrolizumab",
            "Carboplatin",
            "5-Flurouracil",
            "Cisplatin"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07276399"
        },
        {
          "nct_id": "NCT07227025",
          "title": "A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Olomorasib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07227025"
        },
        {
          "nct_id": "NCT05379595",
          "title": "A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Advanced or Metastatic Colorectal Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab IV",
            "Fluorouracil",
            "Leucovorin",
            "Oxaliplatin",
            "Irinotecan",
            "Amivantamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05379595"
        },
        {
          "nct_id": "NCT06662786",
          "title": "A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Colorectal Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Cetuximab",
            "5-fluorouracil",
            "Leucovorin calcium/Levoleucovorin",
            "Oxaliplatin",
            "Irinotecan Hydrochloride"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06662786"
        },
        {
          "nct_id": "NCT04965090",
          "title": "A Phase 2 Single-Arm Study of Amivantamab (JNJ-61186372) and Lazertinib in Metastatic EGFR-mutant Lung Cancer With Progressive or New CNS Metastases on Previous Treatment",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Metastatic Non Small Cell Lung Cancer",
            "Recurrent Non Small Cell Lung Cancer"
          ],
          "lead_sponsor": "Memorial Sloan Kettering Cancer Center",
          "collaborators": [
            "Janssen Scientific Affairs, LLC"
          ],
          "interventions": [
            "Amivantamab",
            "Lazertinib"
          ],
          "last_update": "2025-12-18",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04965090"
        },
        {
          "nct_id": "NCT04077463",
          "title": "An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Lazertinib",
            "Amivantamab",
            "Carboplatin",
            "Pemetrexed"
          ],
          "last_update": "2025-12-24",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04077463"
        },
        {
          "nct_id": "NCT06385080",
          "title": "A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Other Therapeutic Agents in Participants With Head and Neck Squamous Cell Carcinoma",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Squamous Cell Carcinoma of Head and Neck"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Pembrolizumab",
            "Paclitaxel",
            "Carboplatin"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06385080"
        },
        {
          "nct_id": "NCT04538664",
          "title": "A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Pemetrexed",
            "Carboplatin",
            "Pemetrexed"
          ],
          "last_update": "2025-12-23",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04538664"
        },
        {
          "nct_id": "NCT05498428",
          "title": "A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Carcinoma, Non-small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Lazertinib",
            "Carboplatin",
            "Pemetrexed",
            "Direct Oral Anticoagulant (DOAC)",
            "Low Molecular Weight Heparin (LMWH)"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05498428"
        },
        {
          "nct_id": "NCT05388669",
          "title": "A Phase 3, Open-label, Randomized Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Patients With EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Advanced or Metastatic Non-small Cell Lung Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Lazertinib",
            "Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)",
            "Amivantamab Intravenous"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05388669"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "RYBREVANT (amivantamab)",
        "amivantamab",
        "RYBREVANT"
      ]
    },
    {
      "asset": "TALVEY + TECVAYLI",
      "indication": "Relapsed Refractory Multiple Myeloma CD38 exposed",
      "phase": null,
      "trial_or_program": "MonumenTAL-6",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT06285318",
          "title": "A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Relapsed/Refractory Multiple Myeloma (RRMM)"
          ],
          "lead_sponsor": "Janssen-Cilag Ltd.",
          "collaborators": [],
          "interventions": [
            "Teclistamab",
            "Talquetamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06285318"
        },
        {
          "nct_id": "NCT06208150",
          "title": "A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Pomalidomide",
            "Teclistamab",
            "Elotuzumab",
            "Dexamethasone",
            "Bortezomib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06208150"
        },
        {
          "nct_id": "NCT05972135",
          "title": "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "SCRI Development Innovations, LLC",
          "collaborators": [
            "Johnson & Johnson"
          ],
          "interventions": [
            "Teclistamab",
            "Talquetamab",
            "Tocilizumab"
          ],
          "last_update": "2025-10-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05972135"
        },
        {
          "nct_id": "NCT07029776",
          "title": "A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma (MM)"
          ],
          "lead_sponsor": "University of Arkansas",
          "collaborators": [
            "Janssen Research & Development, LLC"
          ],
          "interventions": [
            "teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance",
            "melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy"
          ],
          "last_update": "2025-11-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07029776"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "TALVEY + TECVAYLI"
      ]
    },
    {
      "asset": "TALVEY (talquetamab)",
      "indication": "Relapsed Refractory Multiple Myeloma CD38 exposed",
      "phase": null,
      "trial_or_program": "MonumenTAL-6",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT06285318",
          "title": "A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Relapsed/Refractory Multiple Myeloma (RRMM)"
          ],
          "lead_sponsor": "Janssen-Cilag Ltd.",
          "collaborators": [],
          "interventions": [
            "Teclistamab",
            "Talquetamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06285318"
        },
        {
          "nct_id": "NCT06208150",
          "title": "A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Pomalidomide",
            "Teclistamab",
            "Elotuzumab",
            "Dexamethasone",
            "Bortezomib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06208150"
        },
        {
          "nct_id": "NCT03399799",
          "title": "A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Hematological Malignancies"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03399799"
        },
        {
          "nct_id": "NCT05757973",
          "title": "Pre-Approval Access Named Patient Program for Talquetamab (JNJ-64407564) for Treating Physician Use in Relapsed or Refractory Multiple Myeloma",
          "overall_status": "APPROVED_FOR_MARKETING",
          "phase": null,
          "conditions": [
            "Relapsed or Refractory Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab"
          ],
          "last_update": "2025-12-09",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05757973"
        },
        {
          "nct_id": "NCT06577025",
          "title": "A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination With Daratumumab SC (Tal-D) and Teclistamab SC in Combination With Daratumumab SC (Tec-D) Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants With Standard-risk Newly Diagnosed Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Cilta-cel",
            "Talquetamab",
            "Daratumumab",
            "Teclistamab",
            "Bortezomib",
            "Lenalidomide",
            "Dexamethasone",
            "Cyclophosphamide",
            "Fludarabine"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06577025"
        },
        {
          "nct_id": "NCT06500884",
          "title": "A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Relapse Multiple Myeloma",
            "Refractory Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Prophylaxis A",
            "Prophylaxis B",
            "Prophylaxis C"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06500884"
        },
        {
          "nct_id": "NCT04108195",
          "title": "A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects With Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Daratumumab",
            "Talquetamab",
            "Teclistamab",
            "Pomalidomide"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04108195"
        },
        {
          "nct_id": "NCT05503550",
          "title": "Pre-Approval Access Single Patient Request Treatment for Talquetamab for Treating Physician Use in Relapsed or Refractory Multiple Myeloma",
          "overall_status": "NO_LONGER_AVAILABLE",
          "phase": null,
          "conditions": [
            "Relapsed or Refractory Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab"
          ],
          "last_update": "2025-12-16",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05503550"
        },
        {
          "nct_id": "NCT05695508",
          "title": "A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-, Talquetamab-, and JNJ-79635322-based Combination Regimens in Participants With Newly Diagnosed Transplant Eligible Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "University of Heidelberg Medical Center",
          "collaborators": [
            "Janssen Research & Development, LLC",
            "Deutsche Studiengruppe Multiples Myelom (DSMM)"
          ],
          "interventions": [
            "Teclistamab (Tec)",
            "Daratumumab",
            "Dexamethasone",
            "Lenalidomide",
            "Bortezomib",
            "Talquetamab",
            "JNJ-79635322"
          ],
          "last_update": "2025-12-24",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05695508"
        },
        {
          "nct_id": "NCT05972135",
          "title": "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "SCRI Development Innovations, LLC",
          "collaborators": [
            "Johnson & Johnson"
          ],
          "interventions": [
            "Teclistamab",
            "Talquetamab",
            "Tocilizumab"
          ],
          "last_update": "2025-10-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05972135"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "TALVEY (talquetamab)",
        "talquetamab",
        "TALVEY"
      ]
    },
    {
      "asset": "TALVEY (talquetamab)",
      "indication": "Relapsed Refractory Multiple Myeloma A-CD38 Naïve",
      "phase": null,
      "trial_or_program": "MonumenTAL-3",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT06285318",
          "title": "A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Relapsed/Refractory Multiple Myeloma (RRMM)"
          ],
          "lead_sponsor": "Janssen-Cilag Ltd.",
          "collaborators": [],
          "interventions": [
            "Teclistamab",
            "Talquetamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06285318"
        },
        {
          "nct_id": "NCT06208150",
          "title": "A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Pomalidomide",
            "Teclistamab",
            "Elotuzumab",
            "Dexamethasone",
            "Bortezomib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06208150"
        },
        {
          "nct_id": "NCT03399799",
          "title": "A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Hematological Malignancies"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03399799"
        },
        {
          "nct_id": "NCT05757973",
          "title": "Pre-Approval Access Named Patient Program for Talquetamab (JNJ-64407564) for Treating Physician Use in Relapsed or Refractory Multiple Myeloma",
          "overall_status": "APPROVED_FOR_MARKETING",
          "phase": null,
          "conditions": [
            "Relapsed or Refractory Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab"
          ],
          "last_update": "2025-12-09",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05757973"
        },
        {
          "nct_id": "NCT06577025",
          "title": "A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination With Daratumumab SC (Tal-D) and Teclistamab SC in Combination With Daratumumab SC (Tec-D) Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants With Standard-risk Newly Diagnosed Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Cilta-cel",
            "Talquetamab",
            "Daratumumab",
            "Teclistamab",
            "Bortezomib",
            "Lenalidomide",
            "Dexamethasone",
            "Cyclophosphamide",
            "Fludarabine"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06577025"
        },
        {
          "nct_id": "NCT06500884",
          "title": "A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Relapse Multiple Myeloma",
            "Refractory Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Prophylaxis A",
            "Prophylaxis B",
            "Prophylaxis C"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06500884"
        },
        {
          "nct_id": "NCT04108195",
          "title": "A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects With Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Daratumumab",
            "Talquetamab",
            "Teclistamab",
            "Pomalidomide"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04108195"
        },
        {
          "nct_id": "NCT05503550",
          "title": "Pre-Approval Access Single Patient Request Treatment for Talquetamab for Treating Physician Use in Relapsed or Refractory Multiple Myeloma",
          "overall_status": "NO_LONGER_AVAILABLE",
          "phase": null,
          "conditions": [
            "Relapsed or Refractory Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab"
          ],
          "last_update": "2025-12-16",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05503550"
        },
        {
          "nct_id": "NCT05695508",
          "title": "A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-, Talquetamab-, and JNJ-79635322-based Combination Regimens in Participants With Newly Diagnosed Transplant Eligible Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "University of Heidelberg Medical Center",
          "collaborators": [
            "Janssen Research & Development, LLC",
            "Deutsche Studiengruppe Multiples Myelom (DSMM)"
          ],
          "interventions": [
            "Teclistamab (Tec)",
            "Daratumumab",
            "Dexamethasone",
            "Lenalidomide",
            "Bortezomib",
            "Talquetamab",
            "JNJ-79635322"
          ],
          "last_update": "2025-12-24",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05695508"
        },
        {
          "nct_id": "NCT05972135",
          "title": "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "SCRI Development Innovations, LLC",
          "collaborators": [
            "Johnson & Johnson"
          ],
          "interventions": [
            "Teclistamab",
            "Talquetamab",
            "Tocilizumab"
          ],
          "last_update": "2025-10-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05972135"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "TALVEY (talquetamab)",
        "talquetamab",
        "TALVEY"
      ]
    },
    {
      "asset": "TAR-210 (RIS/erdafitinib)",
      "indication": "Intravesical Delivery System for Localized Bladder Cancer",
      "phase": null,
      "trial_or_program": "MoonRISe-1",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT03390504",
          "title": "A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Urothelial Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Erdafitinib",
            "Vinflunine",
            "Docetaxel",
            "Pembrolizumab",
            "Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)"
          ],
          "last_update": "2025-12-22",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03390504"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "TAR-210 (RIS/erdafitinib)",
        "RIS/erdafitinib",
        "TAR-210 (RIS",
        "erdafitinib)"
      ]
    },
    {
      "asset": "TECVAYLI (teclistamab)",
      "indication": "Multiple Myeloma 1-3PLs",
      "phase": null,
      "trial_or_program": "MajesTEC-3",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT06285318",
          "title": "A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Relapsed/Refractory Multiple Myeloma (RRMM)"
          ],
          "lead_sponsor": "Janssen-Cilag Ltd.",
          "collaborators": [],
          "interventions": [
            "Teclistamab",
            "Talquetamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06285318"
        },
        {
          "nct_id": "NCT06208150",
          "title": "A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Pomalidomide",
            "Teclistamab",
            "Elotuzumab",
            "Dexamethasone",
            "Bortezomib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06208150"
        },
        {
          "nct_id": "NCT06251076",
          "title": "Outpatient-based Teclistamab Step-up Dosing in Patients With Relapsed/Refractory Multiple Myeloma: Process Development in Academic and Community Centres, and Evaluating Impact on Caregiver Burden",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Multiple Myeloma",
            "Relapsed Cancer",
            "Refractory Cancer"
          ],
          "lead_sponsor": "University Health Network, Toronto",
          "collaborators": [
            "Janssen Inc."
          ],
          "interventions": [
            "Teclistamab",
            "Tocilizumab"
          ],
          "last_update": "2025-12-10",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06251076"
        },
        {
          "nct_id": "NCT07110844",
          "title": "A Phase 2 Clinical Trial of Teclistamab and Daratumumab in Previously Untreated AL Amyloidosis",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Amyloid Light-chain Amyloidosis"
          ],
          "lead_sponsor": "Suzanne Lentzsch, MD",
          "collaborators": [
            "Janssen Pharmaceuticals"
          ],
          "interventions": [
            "Teclistamab",
            "Daratumumab and Hyaluronidase-fihj"
          ],
          "last_update": "2025-11-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07110844"
        },
        {
          "nct_id": "NCT05083169",
          "title": "A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Daratumumab",
            "Pomalidomide",
            "Dexamethasone",
            "Bortezomib",
            "Teclistamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05083169"
        },
        {
          "nct_id": "NCT04722146",
          "title": "A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Teclistamab",
            "Daratumumab",
            "Pomalidomide",
            "Lenalidomide",
            "Bortezomib",
            "Nirogacestat"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04722146"
        },
        {
          "nct_id": "NCT06425991",
          "title": "A Phase 1 Randomized, Open Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants With Relapsed/Refractory Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Relapsed or Refractory Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Teclistamab"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06425991"
        },
        {
          "nct_id": "NCT06577025",
          "title": "A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination With Daratumumab SC (Tal-D) and Teclistamab SC in Combination With Daratumumab SC (Tec-D) Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants With Standard-risk Newly Diagnosed Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Cilta-cel",
            "Talquetamab",
            "Daratumumab",
            "Teclistamab",
            "Bortezomib",
            "Lenalidomide",
            "Dexamethasone",
            "Cyclophosphamide",
            "Fludarabine"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06577025"
        },
        {
          "nct_id": "NCT05972135",
          "title": "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "SCRI Development Innovations, LLC",
          "collaborators": [
            "Johnson & Johnson"
          ],
          "interventions": [
            "Teclistamab",
            "Talquetamab",
            "Tocilizumab"
          ],
          "last_update": "2025-10-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05972135"
        },
        {
          "nct_id": "NCT06477783",
          "title": "Prospective Observational Study on the Clinical Efficacy of Teclistamab in Patients With Relapsed and Refractory Multiple Myeloma in Belgium",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Multiple Myeloma",
            "Hematologic Diseases"
          ],
          "lead_sponsor": "Universitaire Ziekenhuizen KU Leuven",
          "collaborators": [
            "Janssen Pharmaceutica"
          ],
          "interventions": [
            "Teclistamab"
          ],
          "last_update": "2025-03-12",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06477783"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "TECVAYLI (teclistamab)",
        "teclistamab",
        "TECVAYLI"
      ]
    },
    {
      "asset": "TECVAYLI (teclistamab)",
      "indication": "TE NDMM maintenance",
      "phase": null,
      "trial_or_program": "MajesTEC-4",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT06285318",
          "title": "A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Relapsed/Refractory Multiple Myeloma (RRMM)"
          ],
          "lead_sponsor": "Janssen-Cilag Ltd.",
          "collaborators": [],
          "interventions": [
            "Teclistamab",
            "Talquetamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06285318"
        },
        {
          "nct_id": "NCT06208150",
          "title": "A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Pomalidomide",
            "Teclistamab",
            "Elotuzumab",
            "Dexamethasone",
            "Bortezomib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06208150"
        },
        {
          "nct_id": "NCT06251076",
          "title": "Outpatient-based Teclistamab Step-up Dosing in Patients With Relapsed/Refractory Multiple Myeloma: Process Development in Academic and Community Centres, and Evaluating Impact on Caregiver Burden",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Multiple Myeloma",
            "Relapsed Cancer",
            "Refractory Cancer"
          ],
          "lead_sponsor": "University Health Network, Toronto",
          "collaborators": [
            "Janssen Inc."
          ],
          "interventions": [
            "Teclistamab",
            "Tocilizumab"
          ],
          "last_update": "2025-12-10",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06251076"
        },
        {
          "nct_id": "NCT07110844",
          "title": "A Phase 2 Clinical Trial of Teclistamab and Daratumumab in Previously Untreated AL Amyloidosis",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Amyloid Light-chain Amyloidosis"
          ],
          "lead_sponsor": "Suzanne Lentzsch, MD",
          "collaborators": [
            "Janssen Pharmaceuticals"
          ],
          "interventions": [
            "Teclistamab",
            "Daratumumab and Hyaluronidase-fihj"
          ],
          "last_update": "2025-11-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07110844"
        },
        {
          "nct_id": "NCT05083169",
          "title": "A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Daratumumab",
            "Pomalidomide",
            "Dexamethasone",
            "Bortezomib",
            "Teclistamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05083169"
        },
        {
          "nct_id": "NCT04722146",
          "title": "A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Teclistamab",
            "Daratumumab",
            "Pomalidomide",
            "Lenalidomide",
            "Bortezomib",
            "Nirogacestat"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04722146"
        },
        {
          "nct_id": "NCT06425991",
          "title": "A Phase 1 Randomized, Open Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants With Relapsed/Refractory Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Relapsed or Refractory Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Teclistamab"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06425991"
        },
        {
          "nct_id": "NCT06577025",
          "title": "A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination With Daratumumab SC (Tal-D) and Teclistamab SC in Combination With Daratumumab SC (Tec-D) Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants With Standard-risk Newly Diagnosed Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Cilta-cel",
            "Talquetamab",
            "Daratumumab",
            "Teclistamab",
            "Bortezomib",
            "Lenalidomide",
            "Dexamethasone",
            "Cyclophosphamide",
            "Fludarabine"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06577025"
        },
        {
          "nct_id": "NCT05972135",
          "title": "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "SCRI Development Innovations, LLC",
          "collaborators": [
            "Johnson & Johnson"
          ],
          "interventions": [
            "Teclistamab",
            "Talquetamab",
            "Tocilizumab"
          ],
          "last_update": "2025-10-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05972135"
        },
        {
          "nct_id": "NCT06477783",
          "title": "Prospective Observational Study on the Clinical Efficacy of Teclistamab in Patients With Relapsed and Refractory Multiple Myeloma in Belgium",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Multiple Myeloma",
            "Hematologic Diseases"
          ],
          "lead_sponsor": "Universitaire Ziekenhuizen KU Leuven",
          "collaborators": [
            "Janssen Pharmaceutica"
          ],
          "interventions": [
            "Teclistamab"
          ],
          "last_update": "2025-03-12",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06477783"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "TECVAYLI (teclistamab)",
        "teclistamab",
        "TECVAYLI"
      ]
    },
    {
      "asset": "TECVAYLI (teclistamab)",
      "indication": "TIE NDMM in combination with DR",
      "phase": null,
      "trial_or_program": "MajesTEC-7",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT06285318",
          "title": "A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Relapsed/Refractory Multiple Myeloma (RRMM)"
          ],
          "lead_sponsor": "Janssen-Cilag Ltd.",
          "collaborators": [],
          "interventions": [
            "Teclistamab",
            "Talquetamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06285318"
        },
        {
          "nct_id": "NCT06208150",
          "title": "A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Pomalidomide",
            "Teclistamab",
            "Elotuzumab",
            "Dexamethasone",
            "Bortezomib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06208150"
        },
        {
          "nct_id": "NCT06251076",
          "title": "Outpatient-based Teclistamab Step-up Dosing in Patients With Relapsed/Refractory Multiple Myeloma: Process Development in Academic and Community Centres, and Evaluating Impact on Caregiver Burden",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Multiple Myeloma",
            "Relapsed Cancer",
            "Refractory Cancer"
          ],
          "lead_sponsor": "University Health Network, Toronto",
          "collaborators": [
            "Janssen Inc."
          ],
          "interventions": [
            "Teclistamab",
            "Tocilizumab"
          ],
          "last_update": "2025-12-10",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06251076"
        },
        {
          "nct_id": "NCT07110844",
          "title": "A Phase 2 Clinical Trial of Teclistamab and Daratumumab in Previously Untreated AL Amyloidosis",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Amyloid Light-chain Amyloidosis"
          ],
          "lead_sponsor": "Suzanne Lentzsch, MD",
          "collaborators": [
            "Janssen Pharmaceuticals"
          ],
          "interventions": [
            "Teclistamab",
            "Daratumumab and Hyaluronidase-fihj"
          ],
          "last_update": "2025-11-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07110844"
        },
        {
          "nct_id": "NCT05083169",
          "title": "A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Daratumumab",
            "Pomalidomide",
            "Dexamethasone",
            "Bortezomib",
            "Teclistamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05083169"
        },
        {
          "nct_id": "NCT04722146",
          "title": "A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Teclistamab",
            "Daratumumab",
            "Pomalidomide",
            "Lenalidomide",
            "Bortezomib",
            "Nirogacestat"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04722146"
        },
        {
          "nct_id": "NCT06425991",
          "title": "A Phase 1 Randomized, Open Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants With Relapsed/Refractory Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Relapsed or Refractory Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Teclistamab"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06425991"
        },
        {
          "nct_id": "NCT06577025",
          "title": "A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination With Daratumumab SC (Tal-D) and Teclistamab SC in Combination With Daratumumab SC (Tec-D) Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants With Standard-risk Newly Diagnosed Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Cilta-cel",
            "Talquetamab",
            "Daratumumab",
            "Teclistamab",
            "Bortezomib",
            "Lenalidomide",
            "Dexamethasone",
            "Cyclophosphamide",
            "Fludarabine"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06577025"
        },
        {
          "nct_id": "NCT05972135",
          "title": "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "SCRI Development Innovations, LLC",
          "collaborators": [
            "Johnson & Johnson"
          ],
          "interventions": [
            "Teclistamab",
            "Talquetamab",
            "Tocilizumab"
          ],
          "last_update": "2025-10-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05972135"
        },
        {
          "nct_id": "NCT06477783",
          "title": "Prospective Observational Study on the Clinical Efficacy of Teclistamab in Patients With Relapsed and Refractory Multiple Myeloma in Belgium",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Multiple Myeloma",
            "Hematologic Diseases"
          ],
          "lead_sponsor": "Universitaire Ziekenhuizen KU Leuven",
          "collaborators": [
            "Janssen Pharmaceutica"
          ],
          "interventions": [
            "Teclistamab"
          ],
          "last_update": "2025-03-12",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06477783"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "TECVAYLI (teclistamab)",
        "teclistamab",
        "TECVAYLI"
      ]
    },
    {
      "asset": "TALVEY + TECVAYLI",
      "indication": "TIE NDMM in combination with DR",
      "phase": null,
      "trial_or_program": "MajesTEC-7",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT06285318",
          "title": "A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Relapsed/Refractory Multiple Myeloma (RRMM)"
          ],
          "lead_sponsor": "Janssen-Cilag Ltd.",
          "collaborators": [],
          "interventions": [
            "Teclistamab",
            "Talquetamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06285318"
        },
        {
          "nct_id": "NCT06208150",
          "title": "A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Pomalidomide",
            "Teclistamab",
            "Elotuzumab",
            "Dexamethasone",
            "Bortezomib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06208150"
        },
        {
          "nct_id": "NCT05972135",
          "title": "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "SCRI Development Innovations, LLC",
          "collaborators": [
            "Johnson & Johnson"
          ],
          "interventions": [
            "Teclistamab",
            "Talquetamab",
            "Tocilizumab"
          ],
          "last_update": "2025-10-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05972135"
        },
        {
          "nct_id": "NCT07029776",
          "title": "A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma (MM)"
          ],
          "lead_sponsor": "University of Arkansas",
          "collaborators": [
            "Janssen Research & Development, LLC"
          ],
          "interventions": [
            "teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance",
            "melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy"
          ],
          "last_update": "2025-11-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07029776"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "TALVEY + TECVAYLI"
      ]
    },
    {
      "asset": "TECVAYLI (teclistamab)",
      "indication": "Relapsed Refractory Multiple Myeloma CD38 exposed",
      "phase": null,
      "trial_or_program": "MajesTEC-9",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT06285318",
          "title": "A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Relapsed/Refractory Multiple Myeloma (RRMM)"
          ],
          "lead_sponsor": "Janssen-Cilag Ltd.",
          "collaborators": [],
          "interventions": [
            "Teclistamab",
            "Talquetamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06285318"
        },
        {
          "nct_id": "NCT06208150",
          "title": "A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Pomalidomide",
            "Teclistamab",
            "Elotuzumab",
            "Dexamethasone",
            "Bortezomib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06208150"
        },
        {
          "nct_id": "NCT06251076",
          "title": "Outpatient-based Teclistamab Step-up Dosing in Patients With Relapsed/Refractory Multiple Myeloma: Process Development in Academic and Community Centres, and Evaluating Impact on Caregiver Burden",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Multiple Myeloma",
            "Relapsed Cancer",
            "Refractory Cancer"
          ],
          "lead_sponsor": "University Health Network, Toronto",
          "collaborators": [
            "Janssen Inc."
          ],
          "interventions": [
            "Teclistamab",
            "Tocilizumab"
          ],
          "last_update": "2025-12-10",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06251076"
        },
        {
          "nct_id": "NCT07110844",
          "title": "A Phase 2 Clinical Trial of Teclistamab and Daratumumab in Previously Untreated AL Amyloidosis",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Amyloid Light-chain Amyloidosis"
          ],
          "lead_sponsor": "Suzanne Lentzsch, MD",
          "collaborators": [
            "Janssen Pharmaceuticals"
          ],
          "interventions": [
            "Teclistamab",
            "Daratumumab and Hyaluronidase-fihj"
          ],
          "last_update": "2025-11-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07110844"
        },
        {
          "nct_id": "NCT05083169",
          "title": "A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Daratumumab",
            "Pomalidomide",
            "Dexamethasone",
            "Bortezomib",
            "Teclistamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05083169"
        },
        {
          "nct_id": "NCT04722146",
          "title": "A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Teclistamab",
            "Daratumumab",
            "Pomalidomide",
            "Lenalidomide",
            "Bortezomib",
            "Nirogacestat"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04722146"
        },
        {
          "nct_id": "NCT06425991",
          "title": "A Phase 1 Randomized, Open Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants With Relapsed/Refractory Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Relapsed or Refractory Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Teclistamab"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06425991"
        },
        {
          "nct_id": "NCT06577025",
          "title": "A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination With Daratumumab SC (Tal-D) and Teclistamab SC in Combination With Daratumumab SC (Tec-D) Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants With Standard-risk Newly Diagnosed Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Cilta-cel",
            "Talquetamab",
            "Daratumumab",
            "Teclistamab",
            "Bortezomib",
            "Lenalidomide",
            "Dexamethasone",
            "Cyclophosphamide",
            "Fludarabine"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06577025"
        },
        {
          "nct_id": "NCT05972135",
          "title": "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "SCRI Development Innovations, LLC",
          "collaborators": [
            "Johnson & Johnson"
          ],
          "interventions": [
            "Teclistamab",
            "Talquetamab",
            "Tocilizumab"
          ],
          "last_update": "2025-10-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05972135"
        },
        {
          "nct_id": "NCT06477783",
          "title": "Prospective Observational Study on the Clinical Efficacy of Teclistamab in Patients With Relapsed and Refractory Multiple Myeloma in Belgium",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Multiple Myeloma",
            "Hematologic Diseases"
          ],
          "lead_sponsor": "Universitaire Ziekenhuizen KU Leuven",
          "collaborators": [
            "Janssen Pharmaceutica"
          ],
          "interventions": [
            "Teclistamab"
          ],
          "last_update": "2025-03-12",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06477783"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "TECVAYLI (teclistamab)",
        "teclistamab",
        "TECVAYLI"
      ]
    },
    {
      "asset": "Bleximenib",
      "indication": "Relapsed Refractory Acute Myeloid Leukemia",
      "phase": null,
      "trial_or_program": "ALE1001",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT05453903",
          "title": "A Phase 1b Study of Bleximenib in Combination With AML-Directed Therapies for Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Leukemia, Myeloid, Acute"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Bleximenib",
            "Venetoclax (VEN)",
            "Azacitidine (AZA)",
            "Cytarabine",
            "Daunorubicin or Idarubicin"
          ],
          "last_update": "2025-12-24",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05453903"
        },
        {
          "nct_id": "NCT07295951",
          "title": "An Open-Label Study to Investigate the Absorption, Metabolism, And Excretion (AME) Of 14C-Bleximenib (JNJ-75276617) in Participants With Acute Leukemia",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Acute Lymphoblastic Leukemia",
            "Acute Leukemias",
            "Acute Myeloid Leukemia"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "14C-bleximenib",
            "bleximenib"
          ],
          "last_update": "2025-12-22",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07295951"
        },
        {
          "nct_id": "NCT06852222",
          "title": "A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Leukemia, Myeloid, Acute"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Bleximenib",
            "Venetoclax (VEN)",
            "Azacitidine (AZA)",
            "Placebo"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06852222"
        },
        {
          "nct_id": "NCT04811560",
          "title": "A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants With Acute Leukemia (cAMeLot-1)",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Acute Leukemias",
            "Acute Myeloid Leukemia",
            "Acute Lymphoblastic Leukemia"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Bleximenib"
          ],
          "last_update": "2025-12-10",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04811560"
        },
        {
          "nct_id": "NCT07223814",
          "title": "Bleximenib or Placebo in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for the Treatment of Patients With Newly Diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: a Double-blind Phase 3 Study",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Acute Myeloid Leukemia"
          ],
          "lead_sponsor": "Stichting Hemato-Oncologie voor Volwassenen Nederland",
          "collaborators": [
            "German-Austrian Acute Myeloid Leukemia Study Group"
          ],
          "interventions": [
            "Bleximenib",
            "Cytarabine",
            "Daunorubicin or Idarubicin",
            "Placebo"
          ],
          "last_update": "2025-11-03",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07223814"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "Bleximenib"
      ]
    },
    {
      "asset": "JNJ-0683 (ARX788)",
      "indication": "Breast Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT06224673",
          "title": "Phase II Open-label Study of ARX788 (Anti-HER2 Antibody Drug Conjugate (ADC)) for Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "HER2 Low Breast Carcinoma",
            "Triple Negative Breast Cancer",
            "Hormone-receptor-positive Breast Cancer",
            "Hormone Receptor Positive Breast Carcinoma"
          ],
          "lead_sponsor": "Laura Huppert, MD, BA",
          "collaborators": [
            "Ambrx, Inc."
          ],
          "interventions": [
            "ARX788",
            "Computed Tomography (CT)",
            "Biospecimen Collection",
            "Amiloride"
          ],
          "last_update": "2025-12-17",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06224673"
        },
        {
          "nct_id": "NCT04829604",
          "title": "A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "HER2 Positive Metastatic Breast Cancer"
          ],
          "lead_sponsor": "Ambrx, Inc.",
          "collaborators": [],
          "interventions": [
            "ARX788"
          ],
          "last_update": "2025-11-14",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04829604"
        },
        {
          "nct_id": "NCT05426486",
          "title": "A Randomized, Open Label, Multi-center Phase II-III Neoadjuvant Study Comparing the Efficacy and Safety of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) in Patients With HER2-positive Breast Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "HER2-positive Breast Cancer"
          ],
          "lead_sponsor": "Caigang Liu",
          "collaborators": [],
          "interventions": [
            "ARX788",
            "Pyrotinib maleate",
            "Trastuzumab",
            "Pertuzumab",
            "Docetaxel",
            "Carboplatin"
          ],
          "last_update": "2024-10-30",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05426486"
        },
        {
          "nct_id": "NCT03255070",
          "title": "A Phase 1, Multicenter, Open-label, Multiple Dose-escalation and Expansion Study of ARX788, as Monotherapy in Advanced Solid Tumors With HER2 Expression",
          "overall_status": "COMPLETED",
          "phase": "Phase 1",
          "conditions": [
            "Breast Neoplasms",
            "Gastric Neoplasm",
            "Solid Tumors"
          ],
          "lead_sponsor": "Ambrx, Inc.",
          "collaborators": [],
          "interventions": [
            "ARX788"
          ],
          "last_update": "2024-02-01",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03255070"
        },
        {
          "nct_id": "NCT06578286",
          "title": "Evaluate the Efficacy and Safety of ARX788 in Patients With HER2-positive Advanced Breast Cancer Whose Disease Has Progressed Following T-DXd Therapy",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Breast Cancer"
          ],
          "lead_sponsor": "Fudan University",
          "collaborators": [],
          "interventions": [
            "ARX788"
          ],
          "last_update": "2024-08-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06578286"
        },
        {
          "nct_id": "NCT05041972",
          "title": "A Global Phase 2 Study to Evaluate the Efficacy and Safety of ARX788 for Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors",
          "overall_status": "WITHDRAWN",
          "phase": "Phase 2",
          "conditions": [
            "HER2 Mutation-Related Tumors",
            "HER2 Amplified Solid Tumors"
          ],
          "lead_sponsor": "Ambrx, Inc.",
          "collaborators": [],
          "interventions": [
            "ARX788"
          ],
          "last_update": "2022-09-13",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05041972"
        },
        {
          "nct_id": "NCT05018676",
          "title": "A Single-arm, Single-center Phase II Clinical Study of Recombinant Humanized Anti-HER2 Monoclonal Antibody-AS269 Conjugate (ARX788) in the Treatment of Unresectable and/or Metastatic Breast Cancer With Low Expression of HER2",
          "overall_status": "UNKNOWN",
          "phase": "Phase 2",
          "conditions": [
            "Breast Cancer With Low Expression of HER2"
          ],
          "lead_sponsor": "Fudan University",
          "collaborators": [],
          "interventions": [
            "ARX788"
          ],
          "last_update": "2022-04-25",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05018676"
        },
        {
          "nct_id": "NCT05018702",
          "title": "A Prospective, Single-arm, Single-center Phase II Clinical Study of Recombinant Humanized Anti-HER2 Monoclonal Antibody-AS269 Conjugate (ARX788) in the Treatment of HER2-positive Breast Cancer Patients With Brain Metastases",
          "overall_status": "UNKNOWN",
          "phase": "Phase 2",
          "conditions": [
            "HER2-positive, Metastatic Breast Cancer"
          ],
          "lead_sponsor": "Fudan University",
          "collaborators": [],
          "interventions": [
            "ARX788"
          ],
          "last_update": "2022-06-01",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05018702"
        },
        {
          "nct_id": "NCT06663748",
          "title": "Evaluate the Efficacy and Safety of ARX788 Given Every 6 Weeks in Patients with HER2-positive Advanced Breast Cancer",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "HER2-positive, Metastatic Breast Cancer"
          ],
          "lead_sponsor": "Henan Cancer Hospital",
          "collaborators": [],
          "interventions": [
            "ARX788"
          ],
          "last_update": "2024-10-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06663748"
        },
        {
          "nct_id": "NCT02512237",
          "title": "A Phase 1, Multicenter, Open-label, Multiple Dose-escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects With Advanced Cancers With HER2 Expression",
          "overall_status": "TERMINATED",
          "phase": "Phase 1",
          "conditions": [
            "Breast Neoplasms",
            "Stomach Neoplasms"
          ],
          "lead_sponsor": "Zhejiang Medicine Co., Ltd.",
          "collaborators": [
            "Ambrx, Inc."
          ],
          "interventions": [
            "ARX788"
          ],
          "last_update": "2020-06-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02512237"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "JNJ-0683 (ARX788)",
        "ARX788",
        "JNJ-0683"
      ]
    },
    {
      "asset": "JNJ-1900 (NBTXR3)",
      "indication": "Lung Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": "Nanobiotix",
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT04892173",
          "title": "A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With LA-HNSCC",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Locally Advanced Head and Neck Squamous Cell Carcinoma",
            "Aged"
          ],
          "lead_sponsor": "Johnson & Johnson Enterprise Innovation Inc.",
          "collaborators": [],
          "interventions": [
            "JNJ-90301900 (NBTXR3)",
            "Cetuximab",
            "Radiation Therapy"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04892173"
        },
        {
          "nct_id": "NCT07224152",
          "title": "NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Locally-Advanced Non-Small Cell Lung Cancer"
          ],
          "lead_sponsor": "M.D. Anderson Cancer Center",
          "collaborators": [
            "Nanobiotix"
          ],
          "interventions": [
            "NBTXR3"
          ],
          "last_update": "2025-12-16",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07224152"
        },
        {
          "nct_id": "NCT04862455",
          "title": "Phase II Study of NBTXR3 Activated by Radiation and Combined With Pembrolizumab for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma With Limited PD-L1 Expression or Refractory to PD-1 Blockade",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Metastatic Head and Neck Squamous Cell Carcinoma",
            "Recurrent Head and Neck Squamous Cell Carcinoma"
          ],
          "lead_sponsor": "M.D. Anderson Cancer Center",
          "collaborators": [],
          "interventions": [
            "Hafnium Oxide-containing Nanoparticles NBTXR3",
            "Hypofractionated Radiation Therapy",
            "Pembrolizumab",
            "Stereotactic Body Radiation Therapy"
          ],
          "last_update": "2025-11-21",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04862455"
        },
        {
          "nct_id": "NCT07219212",
          "title": "A Study of JNJ-90301900 in Combination With Concurrent Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Squamous Cell Carcinoma of Head and Neck"
          ],
          "lead_sponsor": "Johnson & Johnson Enterprise Innovation Inc.",
          "collaborators": [],
          "interventions": [
            "JNJ-90301900",
            "Cisplatin",
            "Intensity Modulated Radiation Therapy (IMRT)"
          ],
          "last_update": "2025-12-24",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07219212"
        },
        {
          "nct_id": "NCT05039632",
          "title": "Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Advanced Malignant Solid Neoplasm",
            "Metastatic Malignant Neoplasm in the Liver",
            "Metastatic Malignant Neoplasm in the Lung",
            "Metastatic Malignant Solid Neoplasm"
          ],
          "lead_sponsor": "M.D. Anderson Cancer Center",
          "collaborators": [
            "National Cancer Institute (NCI)"
          ],
          "interventions": [
            "Hafnium Oxide-containing Nanoparticles NBTXR3",
            "Radiation Therapy",
            "Radiation Therapy"
          ],
          "last_update": "2025-11-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05039632"
        },
        {
          "nct_id": "NCT02379845",
          "title": "A Multicenter Randomized, Open-Label Phase II/III Study, To Compare The Efficacy Of NBTXR3, Implanted As Intratumor Injection And Activated By Radiotherapy, Versus Radiotherapy Alone In Patients With Locally Advanced Soft Tissue Sarcoma Of The Extremity And Trunk Wall",
          "overall_status": "COMPLETED",
          "phase": "Phase 3",
          "conditions": [
            "Adult Soft Tissue Sarcoma"
          ],
          "lead_sponsor": "Nanobiotix",
          "collaborators": [
            "PharmaEngine"
          ],
          "interventions": [
            "NBTXR3",
            "Radiation therapy"
          ],
          "last_update": "2021-04-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02379845"
        },
        {
          "nct_id": "NCT04615013",
          "title": "A Phase 1 Study of NBTXR3 Activated by Radiotherapy With Concurrent Chemotherapy for Adenocarcinoma of the Esophagus",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Cervical Esophagus Adenocarcinoma",
            "Clinical Stage II Esophageal Adenocarcinoma AJCC v8",
            "Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8",
            "Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8",
            "Clinical Stage III Esophageal Adenocarcinoma AJCC v8",
            "Gastroesophageal Junction Adenocarcinoma",
            "Pathologic Stage II Esophageal Adenocarcinoma AJCC v8",
            "Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8",
            "Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8",
            "Pathologic Stage III Esophageal Adenocarcinoma AJCC v8"
          ],
          "lead_sponsor": "M.D. Anderson Cancer Center",
          "collaborators": [
            "National Cancer Institute (NCI)"
          ],
          "interventions": [
            "Capecitabine",
            "Carboplatin",
            "Docetaxel",
            "Fluorouracil",
            "Hafnium Oxide-containing Nanoparticles NBTXR3",
            "Intensity-Modulated Radiation Therapy",
            "Leucovorin",
            "Oxaliplatin",
            "Paclitaxel"
          ],
          "last_update": "2025-10-30",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04615013"
        },
        {
          "nct_id": "NCT04484909",
          "title": "Phase I Study of NBTXR3 Activated by Radiotherapy for Locally Advanced or Borderline Resectable Pancreatic Ductal Adenocarcinoma",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Borderline Resectable Pancreatic Adenocarcinoma",
            "Locally Advanced Pancreatic Ductal Adenocarcinoma",
            "Resectable Pancreatic Ductal Adenocarcinoma",
            "Stage III Pancreatic Cancer AJCC v8"
          ],
          "lead_sponsor": "M.D. Anderson Cancer Center",
          "collaborators": [
            "National Cancer Institute (NCI)"
          ],
          "interventions": [
            "Hafnium Oxide-containing Nanoparticles NBTXR3",
            "Radiation Therapy"
          ],
          "last_update": "2025-10-27",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04484909"
        },
        {
          "nct_id": "NCT01433068",
          "title": "An Open-Label, Single Arm, Feasibility And Safety Phase I Study With NBTXR3 Intratumor Implantation (By Injection) And Activated By External Beam Radiation Therapy In Patients With Soft Tissue Sarcoma Of The Extremity And Trunk Wall",
          "overall_status": "COMPLETED",
          "phase": "Phase 1",
          "conditions": [
            "Adult Soft Tissue Sarcoma"
          ],
          "lead_sponsor": "Nanobiotix",
          "collaborators": [],
          "interventions": [
            "NBTXR3"
          ],
          "last_update": "2020-10-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT01433068"
        },
        {
          "nct_id": "NCT04834349",
          "title": "A Phase II Study of Reirradiation With NBTXR3 in Patients With Inoperable Locoregional Recurrent Head and Neck Squamous Cell Carcinoma",
          "overall_status": "WITHDRAWN",
          "phase": "Phase 2",
          "conditions": [
            "Recurrent Head and Neck Squamous Cell Carcinoma",
            "Unresectable Head and Neck Squamous Cell Carcinoma"
          ],
          "lead_sponsor": "M.D. Anderson Cancer Center",
          "collaborators": [],
          "interventions": [
            "Hafnium Oxide-containing Nanoparticles NBTXR3",
            "Intensity-Modulated Proton Therapy",
            "Intensity-Modulated Radiation Therapy",
            "Pembrolizumab",
            "Quality-of-Life Assessment",
            "Questionnaire Administration",
            "Stereotactic Body Radiation Therapy"
          ],
          "last_update": "2023-09-13",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04834349"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "JNJ-1900 (NBTXR3)",
        "NBTXR3",
        "JNJ-1900"
      ]
    },
    {
      "asset": "TALVEY + TECVAYLI",
      "indication": "Relapsed Refractory Multiple Myeloma",
      "phase": null,
      "trial_or_program": "RedirecTT-1",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT06285318",
          "title": "A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Relapsed/Refractory Multiple Myeloma (RRMM)"
          ],
          "lead_sponsor": "Janssen-Cilag Ltd.",
          "collaborators": [],
          "interventions": [
            "Teclistamab",
            "Talquetamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06285318"
        },
        {
          "nct_id": "NCT06208150",
          "title": "A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Pomalidomide",
            "Teclistamab",
            "Elotuzumab",
            "Dexamethasone",
            "Bortezomib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06208150"
        },
        {
          "nct_id": "NCT05972135",
          "title": "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "SCRI Development Innovations, LLC",
          "collaborators": [
            "Johnson & Johnson"
          ],
          "interventions": [
            "Teclistamab",
            "Talquetamab",
            "Tocilizumab"
          ],
          "last_update": "2025-10-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05972135"
        },
        {
          "nct_id": "NCT07029776",
          "title": "A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma (MM)"
          ],
          "lead_sponsor": "University of Arkansas",
          "collaborators": [
            "Janssen Research & Development, LLC"
          ],
          "interventions": [
            "teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance",
            "melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy"
          ],
          "last_update": "2025-11-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07029776"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "TALVEY + TECVAYLI"
      ]
    },
    {
      "asset": "JNJ-0387",
      "indication": "Solid Tumors",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-0387"
      ]
    },
    {
      "asset": "JNJ-0631 (ARX305)",
      "indication": "Renal Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-0631 (ARX305)",
        "ARX305",
        "JNJ-0631"
      ]
    },
    {
      "asset": "JNJ-1493",
      "indication": "Hematological Malignancies",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-1493"
      ]
    },
    {
      "asset": "JNJ-2638",
      "indication": "Gastrointestinal Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-2638"
      ]
    },
    {
      "asset": "JNJ-2761",
      "indication": "Multiple Myeloma",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-2761"
      ]
    },
    {
      "asset": "JNJ-3413",
      "indication": "Lymphoma",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-3413"
      ]
    },
    {
      "asset": "JNJ-4496",
      "indication": "Hematological Malignancies",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-4496"
      ]
    },
    {
      "asset": "JNJ-4680",
      "indication": "Lung Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-4680"
      ]
    },
    {
      "asset": "JNJ-4681",
      "indication": "Hematological Malignancies",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-4681"
      ]
    },
    {
      "asset": "JNJ-4916",
      "indication": "Lung Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-4916"
      ]
    },
    {
      "asset": "JNJ-5322",
      "indication": "Multiple Myeloma",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-5322"
      ]
    },
    {
      "asset": "JNJ-6420",
      "indication": "Prostate Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-6420"
      ]
    },
    {
      "asset": "JNJ-7446",
      "indication": "Lung Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-7446"
      ]
    },
    {
      "asset": "JNJ-8177 (ARX517)",
      "indication": "Prostate Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-8177 (ARX517)",
        "ARX517",
        "JNJ-8177"
      ]
    },
    {
      "asset": "JNJ-8377",
      "indication": "Lymphoma",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-8377"
      ]
    },
    {
      "asset": "JNJ-8543",
      "indication": "Hematological Malignancies",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-8543"
      ]
    },
    {
      "asset": "JNJ-9401",
      "indication": "Prostate Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-9401"
      ]
    },
    {
      "asset": "JNJ-9530",
      "indication": "Hematological Malignancies",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-9530"
      ]
    },
    {
      "asset": "JNJ-9892",
      "indication": "Hematological Malignancies",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-9892"
      ]
    },
    {
      "asset": "JNJ-9968",
      "indication": "Hematological Malignancies",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-9968"
      ]
    },
    {
      "asset": "icotrokinra",
      "indication": "Psoriasis",
      "phase": null,
      "trial_or_program": "ICONIC",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "icotrokinra"
      ]
    },
    {
      "asset": "SIMPONI (golimumab)",
      "indication": "Pediatric Ulcerative Colitis",
      "phase": null,
      "trial_or_program": "PURSUIT 2",
      "partner": "Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "SIMPONI (golimumab)",
        "golimumab",
        "SIMPONI"
      ]
    },
    {
      "asset": "STELARA (ustekinumab)",
      "indication": "Pediatric Crohn's Disease",
      "phase": null,
      "trial_or_program": "UNITI JR",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "STELARA (ustekinumab)",
        "ustekinumab",
        "STELARA"
      ]
    },
    {
      "asset": "STELARA (ustekinumab)",
      "indication": "Pediatric Ulcerative Colitis",
      "phase": null,
      "trial_or_program": "UNIFI JR",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "STELARA (ustekinumab)",
        "ustekinumab",
        "STELARA"
      ]
    },
    {
      "asset": "TREMFYA (guselkumab)",
      "indication": "Pediatric Juvenile Psoriatic Arthritis",
      "phase": null,
      "trial_or_program": null,
      "partner": "MorphoSys AG",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "TREMFYA (guselkumab)",
        "guselkumab",
        "TREMFYA"
      ]
    },
    {
      "asset": "TREMFYA (guselkumab)",
      "indication": "Pediatric Psoriasis",
      "phase": null,
      "trial_or_program": "PROTOSTAR",
      "partner": "MorphoSys AG",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "TREMFYA (guselkumab)",
        "guselkumab",
        "TREMFYA"
      ]
    },
    {
      "asset": "TREMFYA (guselkumab)",
      "indication": "Psoriatic Arthritis Structural Damage",
      "phase": null,
      "trial_or_program": "APEX",
      "partner": "MorphoSys AG",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "TREMFYA (guselkumab)",
        "guselkumab",
        "TREMFYA"
      ]
    },
    {
      "asset": "TREMFYA (guselkumab)",
      "indication": "Ulcerative Colitis Subcutaneous Induction",
      "phase": null,
      "trial_or_program": "ASTRO",
      "partner": "MorphoSys AG",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "TREMFYA (guselkumab)",
        "guselkumab",
        "TREMFYA"
      ]
    },
    {
      "asset": "icotrokinra",
      "indication": "Psoriatic Arthritis",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "icotrokinra"
      ]
    },
    {
      "asset": "nipocalimab",
      "indication": "Warm Autoimmune Hemolytic Anemia",
      "phase": null,
      "trial_or_program": "ENERGY",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "nipocalimab"
      ]
    },
    {
      "asset": "nipocalimab",
      "indication": "Sjogren's Disease",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "nipocalimab"
      ]
    },
    {
      "asset": "nipocalimab",
      "indication": "Hemolytic Disease of the Fetus and Newborn",
      "phase": null,
      "trial_or_program": "AZALEA",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "nipocalimab"
      ]
    },
    {
      "asset": "nipocalimab",
      "indication": "Fetal and Neonatal Alloimmune Thrombocytopenia",
      "phase": null,
      "trial_or_program": "FREESIA",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "nipocalimab"
      ]
    },
    {
      "asset": "TREMFYA (guselkumab)",
      "indication": "Pediatric Ulcerative Colitis",
      "phase": null,
      "trial_or_program": "QUASAR JR",
      "partner": "MorphoSys AG",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "TREMFYA (guselkumab)",
        "guselkumab",
        "TREMFYA"
      ]
    },
    {
      "asset": "icotrokinra",
      "indication": "Ulcerative Colitis",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "icotrokinra"
      ]
    },
    {
      "asset": "JNJ-4804 Co-antibody Therapy",
      "indication": "Ulcerative Colitis",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-4804 Co-antibody Therapy"
      ]
    },
    {
      "asset": "JNJ-4804 Co-antibody Therapy",
      "indication": "Psoriatic Arthritis",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-4804 Co-antibody Therapy"
      ]
    },
    {
      "asset": "JNJ-4804 Co-antibody Therapy",
      "indication": "Crohn's Disease",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-4804 Co-antibody Therapy"
      ]
    },
    {
      "asset": "JNJ-5939",
      "indication": "Atopic Dermatitis",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-5939"
      ]
    },
    {
      "asset": "nipocalimab",
      "indication": "Systemic Lupus Erythematosus",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "nipocalimab"
      ]
    },
    {
      "asset": "nipocalimab",
      "indication": "Idiopathic Inflammatory Myopathy",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "nipocalimab"
      ]
    },
    {
      "asset": "JNJ-5108",
      "indication": "Immunological Diseases",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-5108"
      ]
    },
    {
      "asset": "JNJ-6848",
      "indication": "Immunological Diseases",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-6848"
      ]
    },
    {
      "asset": "JNJ-7528",
      "indication": "Atopic Dermatitis",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-7528"
      ]
    },
    {
      "asset": "CAPLYTA (lumateperone)",
      "indication": "Adjunctive Treatment for Major Depressive Disorder",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "CAPLYTA (lumateperone)",
        "lumateperone",
        "CAPLYTA"
      ]
    },
    {
      "asset": "IMAAVY (nipocalimab)",
      "indication": "Generalized Myasthenia Gravis",
      "phase": null,
      "trial_or_program": "Vivacity MG3",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "IMAAVY (nipocalimab)",
        "nipocalimab",
        "IMAAVY"
      ]
    },
    {
      "asset": "IMAAVY (nipocalimab)",
      "indication": "Generalized Myasthenia Gravis Pediatrics",
      "phase": null,
      "trial_or_program": "VIBRANCE MG",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "IMAAVY (nipocalimab)",
        "nipocalimab",
        "IMAAVY"
      ]
    },
    {
      "asset": "SPRAVATO (esketamine)",
      "indication": "Treatment Resistant Depression monotherapy",
      "phase": null,
      "trial_or_program": "TRD4005",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "SPRAVATO (esketamine)",
        "esketamine",
        "SPRAVATO"
      ]
    },
    {
      "asset": "CAPLYTA (lumateperone)",
      "indication": "Bipolar Mania",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "CAPLYTA (lumateperone)",
        "lumateperone",
        "CAPLYTA"
      ]
    },
    {
      "asset": "CAPLYTA (lumateperone)",
      "indication": "Pediatric Psychiatric Indications",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "CAPLYTA (lumateperone)",
        "lumateperone",
        "CAPLYTA"
      ]
    },
    {
      "asset": "nipocalimab",
      "indication": "Chronic Inflammatory Demyelinating Polyneuropathy",
      "phase": null,
      "trial_or_program": "ARISE",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "nipocalimab"
      ]
    },
    {
      "asset": "RPGR Gene Therapy",
      "indication": "Retinitis Pigmentosa",
      "phase": null,
      "trial_or_program": "LUMEOS",
      "partner": "UCL Business Plc",
      "notes": "AAV-RPGR",
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "RPGR Gene Therapy"
      ]
    },
    {
      "asset": "seltorexant",
      "indication": "Adjunctive Treatment for Major Depressive Disorder with Insomnia Symptoms",
      "phase": null,
      "trial_or_program": "OARS",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "seltorexant"
      ]
    },
    {
      "asset": "ITI-1284",
      "indication": "Generalized Anxiety Disorder",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "ITI-1284"
      ]
    },
    {
      "asset": "ITI-1284",
      "indication": "Alzheimer's Disease-Related Psychosis",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "ITI-1284"
      ]
    },
    {
      "asset": "ITI-1284",
      "indication": "Alzheimer's Disease-Related Agitation",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "ITI-1284"
      ]
    },
    {
      "asset": "JNJ-1887 sCD59",
      "indication": "Geographic Atrophy",
      "phase": null,
      "trial_or_program": null,
      "partner": "Hemera Biosciences",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-1887 sCD59"
      ]
    },
    {
      "asset": "JNJ-2056 (tau active immunotherapy)",
      "indication": "Alzheimer's Disease",
      "phase": null,
      "trial_or_program": "RETAIN",
      "partner": "AC Immune SA",
      "notes": "AC Immune ACI-35.030",
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-2056 (tau active immunotherapy)",
        "tau active immunotherapy",
        "JNJ-2056"
      ]
    },
    {
      "asset": "JNJ-5120",
      "indication": "Major Depressive Disorder",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-5120"
      ]
    },
    {
      "asset": "posdinemab",
      "indication": "Alzheimer's Disease",
      "phase": null,
      "trial_or_program": "AUTONOMY",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "posdinemab"
      ]
    },
    {
      "asset": "SPRAVATO (esketamine)",
      "indication": "Major Depressive Disorder with Suicidal Ideation Pediatrics",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "SPRAVATO (esketamine)",
        "esketamine",
        "SPRAVATO"
      ]
    },
    {
      "asset": "CABENUVA",
      "indication": "HIV Adolescents",
      "phase": null,
      "trial_or_program": null,
      "partner": "ViiV Healthcare",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "CABENUVA"
      ]
    },
    {
      "asset": "UPTRAVI (selexipag)",
      "indication": "Pediatric Pulmonary Arterial Hypertension",
      "phase": null,
      "trial_or_program": "SALTO",
      "partner": "Nippon Shinyaku",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "UPTRAVI (selexipag)",
        "selexipag",
        "UPTRAVI"
      ]
    },
    {
      "asset": "macitentan",
      "indication": "Pulmonary Arterial Hypertension 75mg",
      "phase": null,
      "trial_or_program": "UNISUS",
      "partner": "Nippon Shinyaku",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "macitentan"
      ]
    },
    {
      "asset": "milvexian (Factor Xla)",
      "indication": "Secondary Stroke Prevention",
      "phase": null,
      "trial_or_program": null,
      "partner": "Bristol Myers Squibb",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "milvexian (Factor Xla)",
        "Factor Xla",
        "milvexian"
      ]
    },
    {
      "asset": "milvexian (Factor Xla)",
      "indication": "Acute Coronary Syndrome",
      "phase": null,
      "trial_or_program": null,
      "partner": "Bristol Myers Squibb",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "milvexian (Factor Xla)",
        "Factor Xla",
        "milvexian"
      ]
    },
    {
      "asset": "milvexian (Factor Xla)",
      "indication": "Atrial Fibrillation",
      "phase": null,
      "trial_or_program": null,
      "partner": "Bristol Myers Squibb",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "milvexian (Factor Xla)",
        "Factor Xla",
        "milvexian"
      ]
    },
    {
      "asset": "SIRTURO",
      "indication": "Leprosy",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "SIRTURO"
      ]
    },
    {
      "asset": "SIRTURO",
      "indication": "Tuberculosis Long Acting",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "SIRTURO"
      ]
    }
  ],
  "_meta": {
    "run_date_utc": "2026-01-08",
    "source_url": "https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf",
    "input_text_sha256": "c8346bd17a91794d9b776b0953bb625a6580b4ee8d53710ed2d456500a7a481d",
    "ocr_max_pages": 12,
    "ocr_dpi": 220,
    "source_type": "jnj_q4cdn_auto",
    "stored_pdf_path": "sources/jnj/2026-01-08.pdf",
    "source_sha256": "7be7a71814f547e8772f826b14552f40244c9d6a9dd0548d8b79a85c3f1a9e04",
    "doc_unchanged": true,
    "doc_unchanged_note": "Source PDF SHA256 unchanged; reused prior snapshot to avoid extraction variability.",
    "extraction_ok": true,
    "ctgov": {
      "enabled": true,
      "queried_assets": [
        "AKEEGA (niraparib/abiraterone)",
        "DARZALEX (daratumumab)",
        "IMBRUVICA (ibrutinib)",
        "INLEXZO (gemcitabine intravesical system)",
        "RYBREVANT (amivantamab)",
        "Bleximenib",
        "CARVYKTI (Ciltacabtagene autoleucel)",
        "ERLEADA (apalutamide)",
        "JNJ-1900 (NBTXR3)",
        "pasritamig",
        "TALVEY + TECVAYLI",
        "TALVEY (talquetamab)",
        "TAR-210 (RIS/erdafitinib)",
        "TECVAYLI (teclistamab)",
        "JNJ-0683 (ARX788)",
        "JNJ-0387",
        "JNJ-0631 (ARX305)",
        "JNJ-1493",
        "JNJ-2638",
        "JNJ-2761",
        "JNJ-3413",
        "JNJ-4496",
        "JNJ-4680"
      ],
      "queries_executed": 51,
      "programs_total": 101,
      "programs_with_matches": 32,
      "phase_mismatches": 0,
      "phase_mismatch_examples": [],
      "sources_path": "sources/jnj/ctgov/2026-01-08",
      "api_base": "https://clinicaltrials.gov/api/v2"
    },
    "sec_edgar": {
      "enabled": true,
      "since_date": "2025-10-10",
      "forms": [
        "10-K",
        "10-Q",
        "8-K",
        "6-K",
        "20-F"
      ],
      "filings_considered": 0,
      "filings_with_events": 0,
      "sources_path": "sources/jnj/sec/2026-01-08",
      "deduped_accessions_count": 2
    },
    "press": {
      "enabled": true,
      "feed_url": "https://www.jnj.com/rss-feed/all",
      "links_scanned": 10,
      "new_releases_processed": 0,
      "releases_with_extracted_events": 0,
      "processed_skipped": 10,
      "sources_path": "sources/jnj/press/2026-01-08"
    }
  }
}